<SEC-DOCUMENT>0001104659-23-041009.txt : 20230403
<SEC-HEADER>0001104659-23-041009.hdr.sgml : 20230403
<ACCEPTANCE-DATETIME>20230403172840
ACCESSION NUMBER:		0001104659-23-041009
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20230331
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230403
DATE AS OF CHANGE:		20230403

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Annovis Bio, Inc.
		CENTRAL INDEX KEY:			0001477845
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262540421
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39202
		FILM NUMBER:		23794034

	BUSINESS ADDRESS:	
		STREET 1:		1055 WESTLAKES DRIVE, SUITE 300
		CITY:			BERWYN
		STATE:			PA
		ZIP:			19312
		BUSINESS PHONE:		610-727-3913

	MAIL ADDRESS:	
		STREET 1:		1055 WESTLAKES DRIVE, SUITE 300
		CITY:			BERWYN
		STATE:			PA
		ZIP:			19312

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	QR Pharma, Inc.
		DATE OF NAME CHANGE:	20091202
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2311180d2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ANVS="http://annovisbio.com/20230331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_ANVS_annovisbio.com_20230331 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20230331_20230331 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0001477845 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-03-31to2023-03-31" name="dei:EntityCentralIndexKey">0001477845</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-03-31to2023-03-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="anvs-20230331.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-03-31to2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-31</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>



<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: Black 0.75pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 18pt"><b>FORM <span id="xdx_905_edei--DocumentType_c20230331__20230331_zPj5czqt55fd"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: Black 0.75pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d) of the</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities Exchange Act of 1934</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of report (Date of earliest event reported):
<span id="xdx_907_edei--DocumentPeriodEndDate_c20230331__20230331_z1lPufjtZ8Qi"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 31, 2023</ix:nonNumeric></span></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: Black 0.75pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 21pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityRegistrantName_c20230331__20230331_zdXAvgfs8Wne"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" name="dei:EntityRegistrantName">ANNOVIS BIO, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact Name of Registrant as Specified in Charter)</b><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: Black 0.75pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="text-align: center; width: 33%">&#160;</td>
    <td style="text-align: center; width: 34%">&#160;</td>
    <td style="text-align: center; width: 33%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20230331__20230331_zGyculvGKAL6"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="vertical-align: top; text-align: center"><b><span id="xdx_909_edei--EntityFileNumber_c20230331__20230331_zkq5DiPYDKrh"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" name="dei:EntityFileNumber">001-39202</ix:nonNumeric></span></b></td>
    <td style="vertical-align: top; text-align: center"><b><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20230331__20230331_zmayTcuZpKSc"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" name="dei:EntityTaxIdentificationNumber">26-2540421</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="text-align: center; vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(State or Other Jurisdiction</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>of Incorporation)</b></p></td>
    <td style="text-align: center; vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Commission</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>File Number)</b></p></td>
    <td style="text-align: center; vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(I.R.S. Employer</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Identification No.)</b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90D_edei--EntityAddressAddressLine1_c20230331__20230331_ztb3Erc2z4j9"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" name="dei:EntityAddressAddressLine1">1055 Westlakes Drive</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressAddressLine2_c20230331__20230331_zTlYV8XsStMc"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" name="dei:EntityAddressAddressLine2">Suite 300</ix:nonNumeric></span><br />
<span id="xdx_907_edei--EntityAddressCityOrTown_c20230331__20230331_zJZdd2q2fsa5"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" name="dei:EntityAddressCityOrTown">Berwyn</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20230331__20230331_zv77p6fUeGMj"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" name="dei:EntityAddressStateOrProvince">PA</ix:nonNumeric></span> <span id="xdx_902_edei--EntityAddressPostalZipCode_c20230331__20230331_zIfz6hkaUHE"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" name="dei:EntityAddressPostalZipCode">19312</ix:nonNumeric> </span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address of Principal Executive Offices, and
Zip Code)</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90C_edei--CityAreaCode_c20230331__20230331_ziKL4yZXWdO2"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" name="dei:CityAreaCode">610</ix:nonNumeric></span>) <span id="xdx_902_edei--LocalPhoneNumber_c20230331__20230331_zMHiUXzKTLpb"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" name="dei:LocalPhoneNumber">727-3913</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s Telephone Number, Including
Area Code</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Not
Applicable&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former Name or Former Address, if Changed Since
Last Report)</b>&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: Black 1pt solid; width: 37%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><b>Title of each class</b></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 24%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><b>Trading Symbol(s)</b></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 39%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><b>Name
    of each exchange on which<br />
 registered</b></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><b><span id="xdx_901_edei--Security12bTitle_c20230331__20230331_ziIAe4A96Kia"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" name="dei:Security12bTitle">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></b></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><b><span id="xdx_90C_edei--TradingSymbol_c20230331__20230331_zc5XOWBp7bqk"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" name="dei:TradingSymbol">ANVS</ix:nonNumeric></span></b></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><b><span id="xdx_904_edei--SecurityExchangeName_c20230331__20230331_zcqtSvgD3983"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">New York Stock Exchange</ix:nonNumeric></span></b></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: Black 0.75pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see</i> General Instruction
A.2. below):</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 4%">&#160;</td>
    <td style="vertical-align: top; width: 4%"><span style="font-family: Wingdings"><span id="xdx_903_edei--WrittenCommunications_c20230331__20230331_zmFHk0KxjJD7"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="vertical-align: top; width: 92%">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>
  </table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 4%">&#160;</td>
    <td style="vertical-align: top; width: 4%"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_903_edei--SolicitingMaterial_c20230331__20230331_zBL8b8X6bYw6"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="vertical-align: top; width: 92%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
  </table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 4%">&#160;</td>
    <td style="vertical-align: top; width: 4%"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_904_edei--PreCommencementTenderOffer_c20230331__20230331_zVnkEKxWVg83"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="vertical-align: top; width: 92%">Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
  </table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 4%"></td><td style="width: 4%; text-align: left"><span style="font-family: Wingdings"><span id="xdx_904_edei--PreCommencementIssuerTenderOffer_c20230331__20230331_zRSzINtR7f47"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: left; width: 92%">Pre-commencement communication pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))</td>
</tr></table>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Emerging growth company <span style="font-family: Wingdings"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20230331__20230331_zL0IpYCzTr3e"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#120;</ix:nonNumeric></span>
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings"><span id="xdx_90A_edei--EntityExTransitionPeriod_c20230331__20230331_z0LeUNH6vVo1"><ix:nonNumeric contextRef="From2023-03-31to2023-03-31" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod">&#120;</ix:nonNumeric></span>
</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 1.01</b></span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry into a Material Definitive Agreement.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">On March 31, 2023, Annovis Bio, Inc. (the
&#8220;Company&#8221;), entered into an ATM Equity Offering Sales Agreement<sup>SM</sup>&#160;(the &#8220;Sales Agreement&#8221;) with&#160;BofA&#160;Securities,
Inc. (&#8220;BofA&#8221;) and ThinkEquity LLC (&#8220;ThinkEquity&#8221; and, together with BofA, the &#8220;Sales Agents&#8221;), as
sales agents, pursuant to which the Company may offer and sell, from time to time through&#160;the Sales Agents, shares of the Company&#8217;s
common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $50.0 million
(the &#8220;Shares&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The offer and sale of the Shares will be made
pursuant to a shelf registration statement on Form&#160;S-3&#160;and the related prospectus (File&#160;No. 333-252625)&#160;filed by the
Company with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on February 1, 2021 and declared effective by the SEC on February
11, 2021, as supplemented by a prospectus supplement dated March 31, 2023 and filed with the SEC pursuant to Rule&#160;424(b)&#160;under
the&#160;Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Pursuant to the Sales Agreement,&#160;the
Sales Agents&#160;may sell the Shares by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in
Rule&#160;415&#160;of the&#160;Securities Act, including sales made by means of ordinary brokers&#8217; transactions, including on the
New York Stock Exchange, at market prices or as otherwise agreed with&#160;the Sales Agents.&#160;The Sales Agents&#160;will use commercially
reasonable efforts consistent with its normal trading and sales practices to sell the Shares from time to time, based upon instructions
from the Company, including any price or size limits or other customary parameters or conditions the Company may impose.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Company is not obligated to make any sales
of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the termination of
the Sales Agreement by&#160;the Sales Agents&#160;or the Company, as permitted therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Company will pay&#160;the Sales Agents&#160;a
commission rate of up to 2.0% of the aggregate gross proceeds from each sale of Shares and has agreed to provide&#160;the Sales Agents&#160;with
customary indemnification and contribution rights. The Company will also reimburse&#160;the Sales Agents&#160;for certain specified expenses
in connection with entering into the Sales Agreement. The Sales Agreement contains customary representations and warranties and conditions
to the placements of the Shares pursuant thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The foregoing description of the Sales Agreement
is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as
Exhibit 1.1 to this Current Report on Form&#160;8-K&#160;and is incorporated herein by reference. The opinion of the Company&#8217;s counsel
regarding the validity of the Shares that will be issued pursuant to the Sales Agreement is also filed herewith as Exhibit 5.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This Current Report on Form&#160;8-K&#160;shall
not constitute an offer to sell or the solicitation of an offer to buy the Common Stock discussed herein, nor shall there be any offer,
solicitation, or sale of common stock in any state in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><b>Item 9.01</b></td>
    <td style="width: 90%"><b>Financial Statements and Exhibits.</b></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(d) Exhibits. &#160;</p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 6%">
    <p style="border-bottom: Black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exhibit<br />
Number</b></p></td>
    <td style="width: 2%; padding-bottom: 6pt">&#160;</td>
    <td style="width: 92%">
    <p style="border-bottom: Black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Description</b></p></td></tr>
  <tr>
    <td style="padding-top: 4pt; vertical-align: top"><a href="tm2311180d2_ex1-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></a></td>
    <td style="padding-top: 4pt; vertical-align: bottom">&#160;</td>
    <td style="padding-top: 4pt; vertical-align: top; padding-bottom: 6pt"><a href="tm2311180d2_ex1-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At-the-Market&#160;Equity&#160;Offering&#160;Sales&#160;Agreement, dated March 31, 2023, by and among Annovis Bio, Inc.,&#160;BofA&#160;Securities, Inc. and ThinkEquity LLC.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2311180d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 6pt"><a href="tm2311180d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Duane Morris LLP regarding the legality of shares.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2311180d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 6pt"><a href="tm2311180d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Duane Morris LLP (included in Exhibit 5.1).</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table>
<p style="margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">SIGNATURES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="vertical-align: top">&#160;</td>
<td colspan="2" style="vertical-align: bottom"><b>ANNOVIS BIO, INC.</b></td></tr>
<tr>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr>
<td style="vertical-align: top; width: 50%">Date: April 3, 2023</td>
<td style="vertical-align: bottom; width: 4%">By:</td>
<td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 46%">/s/ Henry Hagopian, III &#160;</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom">Name: Henry Hagopian, III</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom">Title: Chief Financial Officer</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>


</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LbOriLpLhw5xigwRb4uLUtyakda/R/ItrRtiCITknC9HiIHIaWlqZDjOywL22LS19gglnpHRnjA4stU6hTBLvBjnWVvfrT8wo8BgYMbxTId757wbh1UKcjJU06FKQKp0JGG3EdFXz8ieTYXWG12DthXsmFo26DW/+g97/SRLzatLOiA7QzaFJJa9/AYlEwVbuusH8dVBUWQiGnQViZzp1n5jbs5TA4sam5DlevTf0QfhNEke -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2311180d2_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B><I><U>EXECUTION
VERSION</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ANNOVIS BIO,&nbsp;INC.</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common Stock<BR>
($0.0001 par value)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATM
EQUITY OFFERING</B></FONT><B><FONT STYLE="font-size: 10pt"><SUP>SM</SUP></FONT> SALES AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">March&nbsp;31, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BofA Securities,&nbsp;Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ThinkEquity LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">c/o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">BofA Securities,&nbsp;Inc.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">One Bryant Park</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">New York, New York 10036</FONT></TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, New York, New York 10036Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">c/o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ThinkEquity LLC</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">17 State Street, 41st Floor</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">New York, New York 10004</FONT></TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annovis
Bio,&nbsp;Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), proposes, subject to the terms and conditions stated herein,
to issue and sell from time to time to or through BofA Securities,&nbsp;Inc. (&ldquo;<U>BofA</U>&rdquo;) or ThinkEquity LLC (&ldquo;<U>ThinkEquity</U>&rdquo;),
as sales agents and/or principals (each an &ldquo;Agent&rdquo;, and collectively, the &ldquo;<U>Agents</U>&rdquo;), shares (the &ldquo;<U>Shares</U>&rdquo;<I>)
</I>of the Company&rsquo;s common stock, $0.0001 par value (the &ldquo;<U>Common Stock</U>&rdquo;), having an aggregate gross sales price
of not to exceed $50,000,000, on the terms set forth in this ATM Equity Offering</FONT><FONT STYLE="font-size: 10pt"><SUP>SM</SUP></FONT>
Sales Agreement. The Company agrees that whenever it determines to sell Shares directly to an Agent or Agents as principal(s)&nbsp;it
will enter into a separate written Terms Agreement (each, a &ldquo;<U>Terms Agreement</U>&rdquo;), in substantially the form of Annex
I hereto, relating to such sale in accordance with Section&nbsp;2(j)&nbsp;hereof. References herein to &ldquo;this Agreement&rdquo; or
to matters contained &ldquo;herein&rdquo; or &ldquo;hereunder&rdquo;, or words of similar import, mean this ATM Equity Offering <FONT STYLE="font-size: 10pt"><SUP>SM</SUP></FONT>
Sales Agreement and any applicable Terms Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company has prepared and filed with the Securities
and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) a shelf registration statement on Form&nbsp;S-3 (File No.&nbsp;252625),
covering the public offering and sale of certain securities of the Company, including the Shares, under the Securities Act of 1933, as
amended (the &ldquo;<U>1933 Act</U>&rdquo;) and the rules&nbsp;and regulations promulgated thereunder (the &ldquo;<U>1933 Act Regulations</U>&rdquo;),
which shelf registration statement was declared effective by the Commission on February&nbsp;11, 2021. The &ldquo;Registration Statement&rdquo;,
as of any time, means such registration statement as amended by any post-effective amendments thereto at such time, including the exhibits
and any schedules thereto at such time, the documents incorporated or deemed to be incorporated by reference therein at such time pursuant
to Item 12 of Form&nbsp;S-3 under the 1933 Act and the documents otherwise deemed to be a part thereof as of such time pursuant to Rule&nbsp;430B
of the 1933 Act Regulations (&ldquo;<U>Rule&nbsp;430B</U>&rdquo;); provided, however, that the &ldquo;Registration Statement&rdquo; without
reference to a time means such registration statement as amended by any post-effective amendments thereto as of the time of the first
contract of sale for the Shares, which time shall be considered the &ldquo;new effective date&rdquo; of the Registration Statement with
respect to the Shares within the meaning of paragraph (f)(2)&nbsp;of Rule&nbsp;430B (&ldquo;<U>Rule&nbsp;430B(f)(2)</U>&rdquo;), including
the exhibits and schedules thereto at such time, the documents incorporated or deemed to be incorporated by reference therein at such
time pursuant to Item 12 of Form&nbsp;S-3 under the 1933 Act and the documents otherwise deemed to be a part thereof as of such time pursuant
to Rule&nbsp;430B. The base prospectus filed as part of such shelf registration statement, as amended in the form in which it has been
filed most recently with the Commission in accordance with Section&nbsp;3(b)&nbsp;or 3(c)&nbsp;hereof, including the documents incorporated
or deemed to be incorporated by reference therein pursuant to Item 12 of Form&nbsp;S-3 under the 1933 Act, is referred to herein as the
 &ldquo;<U>Base Prospectus</U>&rdquo;. Promptly after execution and delivery of this Agreement, the Company will prepare and file a prospectus
supplement relating to the Shares in accordance with the provisions of Rule&nbsp;424(b)&nbsp;of the 1933 Act Regulations (&ldquo;<U>Rule&nbsp;424(b)</U>&rdquo;).
Such final prospectus supplement, as amended by the prospectus supplement filed most recently with the Commission in accordance with Section&nbsp;3(b),
3(c)&nbsp;or 3(n)&nbsp;hereof, as the case may be, including the documents incorporated or deemed to be</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">incorporated by reference therein
pursuant to Item 12 of Form&nbsp;S-3 under the 1933 Act, is referred to herein as the &ldquo;Prospectus Supplement&rdquo;. The Base Prospectus,
as amended by the Prospectus Supplement and any applicable pricing supplement thereto, in the forms of the Base Prospectus, the Prospectus
Supplement and any such pricing supplement are first furnished to the Agents for use in connection with the offering and sale of Shares,
are collectively referred to herein as the &ldquo;Prospectus.&rdquo; For purposes of this Agreement, all references to the Registration
Statement, any preliminary prospectus or the Prospectus or any amendment or supplement thereto shall be deemed to be the copy filed with
the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval system (or any successor system)(&ldquo;<U>EDGAR</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As used in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;Applicable Time&rdquo; means,
with respect to any offer and sale of Shares, the time immediately prior to the first contract of sale for such Shares, or such other
time as agreed by the Company and the applicable Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;General Disclosure Package&rdquo;
means each Issuer General Use Free Writing Prospectus, if any, issued prior to the Applicable Time, the most recent Prospectus filed with
the Commission in accordance with Section&nbsp;3(b), 3(c)&nbsp;or 3(n)&nbsp;hereof that is distributed to investors prior to the Applicable
Time and the number of Shares and the initial offering price per Share, all considered together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;Issuer Free Writing Prospectus&rdquo;
means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule&nbsp;433 of the 1933 Act Regulations (&ldquo;<U>Rule&nbsp;433</U>&rdquo;),
including, without limitation, any &ldquo;free writing prospectus&rdquo; (as defined in Rule&nbsp;405 under the 1933 Act (&ldquo;<U>Rule&nbsp;405</U>&rdquo;))
relating to the Shares that is (i)&nbsp;required to be filed with the Commission by the Company, (ii)&nbsp;a &ldquo;road show that is
a written communication&rdquo; within the meaning of Rule&nbsp;433(d)(8)(i), whether or not required to be filed with the Commission,
or (iii)&nbsp;exempt from filing with the Commission pursuant to Rule&nbsp;433(d)(5)(i)&nbsp;because it contains a description of the
Shares or of the offering thereof that does not reflect the final terms, in each case in the form filed or required to be filed with the
Commission or, if not required to be filed, in the form retained in the Company&rsquo;s records pursuant to Rule&nbsp;433(g).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;Issuer General Use Free Writing
Prospectus&rdquo; means any Issuer Free Writing Prospectus approved by the Agents or, in the case of a specific offer and sale of Shares,
the applicable Agents pursuant to Section&nbsp;3(l)&nbsp;hereof that is furnished to the Agents or such Agents, as the case may be, for
general distribution to investors, as evidenced by communications between the Company and the Agents or such Agents, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;Issuer Limited Use Free Writing
Prospectus&rdquo; means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All references in this Agreement to financial statements
and schedules and other information which is &ldquo;contained,&rdquo; &ldquo;included,&rdquo; &ldquo;made,&rdquo; &ldquo;stated&rdquo;
or &ldquo;referred to&rdquo; (or other references of like import) in the Registration Statement, any preliminary prospectus or the Prospectus
shall be deemed to include all such financial statements and schedules and other information incorporated or deemed to be incorporated
by reference in the Registration Statement, any preliminary prospectus or the Prospectus, as the case may be, prior to the Applicable
Time relating to the particular Shares; and all references in this Agreement to amendments or supplements to the Registration Statement,
any preliminary prospectus or the Prospectus shall be deemed to include the filing of any document under the Securities Exchange Act of
1934, as amended (the &ldquo;<U>1934 Act</U>&rdquo;), and the rules&nbsp;and regulations promulgated thereunder (the &ldquo;<U>1934 Act
Regulations</U>&rdquo;) incorporated or deemed to be incorporated by reference in the Registration Statement, such preliminary prospectus
or the Prospectus, as the case may be, at or after the Applicable Time relating to the particular Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;1.
</FONT><U>Representations and Warranties</U>. The Company represents and warrants to the Agents at the date of this Agreement, each Registration
Statement Amendment Date (as defined in Section&nbsp;3(o)&nbsp;hereof), each Company Periodic Report Date (as defined in Section&nbsp;3(n)&nbsp;hereof),
each Company Earnings Report Date (as defined in Section&nbsp;3(o)&nbsp;hereof), each Request Date (as defined in Section&nbsp;3(o)&nbsp;hereof),
each Applicable Time and each Settlement Date (as defined in Section&nbsp;2(g)&nbsp;hereof) (collectively, a &ldquo;<U>Representation
Date</U>&rdquo;), and agrees with the Agents, as follows:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compliance
of the Registration Statement, the Prospectus and Incorporated Documents</U>. The Company meets the requirements for use of Form&nbsp;S-3
under the 1933 Act. The Registration Statement is a shelf registration statement and the Shares have been and remain eligible for registration
by the Company on such shelf registration statement. Each of the Registration Statement and any post-effective amendment thereto has become
effective under the 1933 Act. No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment
thereto has been issued under the 1933 Act, no notice of objection of the Commission to the use of the Registration Statement or any post-effective
amendment thereto pursuant to Rule&nbsp;401(g)(1)&nbsp;of the 1933 Act Regulations (&ldquo;<U>Rule&nbsp;401(g)(1)</U>&rdquo;) has been
received by the Company, no order preventing or suspending the use of any preliminary prospectus or the Prospectus or any amendment or
supplement thereto has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company&rsquo;s
knowledge, contemplated. The Company has complied with each request (if any) from the Commission for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Each of the Registration Statement and
any post-effective amendment thereto, at the time of its effectiveness and as of each deemed effective date with respect to the Agents
pursuant to Rule&nbsp;430B(f)(2), complied in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations.
Each of any preliminary prospectus and the Prospectus and any amendment or supplement thereto, at the time it was filed with the Commission,
complied in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations and is identical to the electronically
transmitted copy thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">The documents incorporated or deemed
to be incorporated by reference in the Registration Statement, any preliminary prospectus and the Prospectus, when they became effective
or at the time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements
of the 1934 Act and the 1934 Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Accurate
Disclosure</U>. Neither the Registration Statement nor any amendment thereto, at its effective time or at any Settlement Date, contained,
contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required to be
stated therein or necessary to make the statements therein not misleading. At each Applicable Time, neither (A)&nbsp;the General Disclosure
Package nor (B)&nbsp;any individual Issuer Limited Use Free Writing Prospectus, when considered together with the General Disclosure Package,
included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Neither the Prospectus
nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any filing with the Commission
pursuant to Rule&nbsp;424(b)&nbsp;or at any Settlement Date, included, includes or will include an untrue statement of a material fact
or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The documents incorporated or deemed to be incorporated by reference in the Registration Statement,
the General Disclosure Package and the Prospectus, at the time the Registration Statement became effective or when such documents incorporated
by reference were or hereafter are filed with the Commission, as the case may be, when read together with the other information in the
Registration Statement, the General Disclosure Package or the Prospectus, as the case may be, did not, do not and will not include an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Issuer
Free Writing Prospectuses</U>. No Issuer Free Writing Prospectus conflicts or will conflict with the information contained in the Registration
Statement, any preliminary prospectus or the Prospectus or any amendment or supplement thereto, including any document incorporated by
reference therein, that has not been superseded or modified. Any offer that is a written communication relating to the Shares made prior
to the initial filing of the Registration Statement by the Company or any person acting on its behalf (within the meaning, for this paragraph
only, of Rule&nbsp;163(c)&nbsp;of the 1933 Act Regulations) has been filed with the Commission in accordance with the exemption provided
by Rule&nbsp;163 of the 1933 Act Regulations (&ldquo;<U>Rule&nbsp;163</U>&rdquo;) and otherwise complied with the requirements of Rule&nbsp;163,
including, without limitation, the legending requirement, to qualify such offer for the exemption from Section&nbsp;5(c)&nbsp;of the 1933
Act provided by Rule&nbsp;163.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Company
Not Ineligible Issuer</U>. (A)&nbsp;At the time of filing the Registration Statement and any post-effective amendment thereto, (B)&nbsp;at
the earliest time thereafter that the Company or another offering participant made a <I>bona fide</I> offer (within the meaning of Rule&nbsp;164(h)(2)&nbsp;of
the 1933 Act Regulations) of the Shares, (C)&nbsp;at the date of this Agreement and any Terms Agreement and (D)&nbsp;at each Applicable
Time, the Company was not and is not an &ldquo;ineligible issuer,&rdquo; as defined in Rule&nbsp;405, without taking account of any determination
by the Commission pursuant to Rule&nbsp;405 that it is not necessary that the Company be considered an ineligible issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Independent
Accountants</U>. WithumSmith+Brown, PC, who has certified the financial statements and supporting schedules included in the Registration
Statement, the General Disclosure Package and the Prospectus are independent public accountants as required by the 1933 Act, the 1933
Act Regulations, the 1934 Act, the 1934 Act Regulations and the Public Company Accounting Oversight Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Financial
Statements; Non-GAAP Financial Measures</U>. The financial statements of the Company included in the Registration Statement, the General
Disclosure Package and the Prospectus, together with the related schedules and notes, present fairly, in all material respects, the financial
position of the Company at the dates indicated and the statements of operations, statements of cash flows, statements of redeemable convertible
preferred stock and stockholders&rsquo; equity (deficit) of the Company for the periods specified; said financial statements have been
prepared in conformity with U.S. generally accepted accounting principles (&ldquo;<U>GAAP</U>&rdquo;) applied on a consistent basis throughout
the periods involved. The financial statements of the businesses or properties acquired or proposed to be acquired, if any, included in
the Registration Statement, the General Disclosure Package and the Prospectus present fairly in all material respects the information
set forth therein, have been prepared in conformity with GAAP applied on a consistent basis and otherwise have been prepared in accordance
with, in the case of businesses acquired or to be acquired, the applicable financial statement requirements of Rule&nbsp;3-05 or, in the
case of real estate operations acquired or to be acquired, Rule&nbsp;3-14 of Regulation S-X. The supporting schedules, if any, present
fairly in all material respects in accordance with GAAP the information required to be stated therein. The selected financial data and
the summary financial information included in the Registration Statement, the General Disclosure Package and the Prospectus present fairly
in all material respects the information shown therein and have been compiled on a basis consistent with that of the audited financial
statements included therein. Any pro forma financial statements and the related notes thereto included in the Registration Statement,
the General Disclosure Package and the Prospectus present fairly the information shown therein, have been prepared in accordance with
the Commission&rsquo;s rules&nbsp;and guidelines with respect to pro forma financial statements and have been properly compiled on the
bases described therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are appropriate
to give effect to the transactions and circumstances referred to therein. Except as included in the Registration Statement, the General
Disclosure Package and the Prospectus, no historical or pro forma financial statements or supporting schedules are required to be included
in the Registration Statement, any preliminary prospectus or the Prospectus under the 1933 Act or the 1933 Act Regulations. All disclosures
contained in the Registration Statement, the General Disclosure Package or the Prospectus, if any, regarding &ldquo;non-GAAP financial
measures&rdquo; (as such term is defined by the rules&nbsp;and regulations of the Commission) comply with Regulation G under the 1934
Act and Item 10 of Regulation S-K under the 1933 Act, to the extent applicable. The interactive data in eXtensible Business Reporting
Language incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents in
all material respects the required information and has been prepared in accordance with the Commission's rules&nbsp;and guidelines applicable
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Material Adverse Change</U>. Except as stated in the Registration Statement, the General Disclosure Package and the Prospectus, since
the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus,
(A)&nbsp;there has been no material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business
prospects of the Company, whether or not arising in the ordinary course of business (a &ldquo;<U>Material Adverse Change</U>&rdquo;),
(B)&nbsp;there have been no transactions entered into by the Company, other than those in the ordinary course of business, which are material
with respect to the Company, and (C)&nbsp;there has been no </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">dividend or distribution of any kind
declared, paid or made by the Company on any class or series of its capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(viii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Good
Standing of the Company</U>. The Company has been duly organized and is validly existing as a corporation in good standing under the laws
of the State of Delaware and has all requisite power and authority to own, lease and operate its properties and to conduct its business
as described in the Registration Statement, the General Disclosure Package and the Prospectus and to enter into and perform its obligations
under, and to consummate the transactions contemplated in, this Agreement. The Company is duly qualified as a foreign corporation to transact
business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing
of property or the conduct of business, except where the failure so to qualify or to be in good standing would not, singly or in the aggregate,
result in a material adverse effect in (A)&nbsp;the condition, financial or otherwise, or in the earnings, business affairs or business
prospects of the Company, whether or not arising in the ordinary course of business, or (B)&nbsp;the ability of the Company to enter into
and perform any of its obligations under, or to consummate any of the transactions contemplated in, this Agreement (collectively, a &ldquo;<U>Material
Adverse Effect</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ix)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Subsidiaries</U>. The Company has no subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Capitalization;
Listing of Common Stock</U>. The authorized, issued and outstanding shares of capital stock of the Company are as set forth in the Registration
Statement and the Prospectus (except for subsequent issuances, if any, pursuant to this Agreement, pursuant to reservations, agreements
or employee benefit plans referred to in the Registration Statement, the General Disclosure Package and the Prospectus or pursuant to
the exercise of convertible securities or options referred to in the Registration Statement, the General Disclosure Package and the Prospectus).
The outstanding shares of capital stock of the Company have been duly authorized and validly issued and are fully paid and non-assessable.
None of the outstanding shares of capital stock of the Company were issued in violation of the preemptive or other similar rights of any
securityholder of the Company or any other person or entity. The Company&rsquo;s Common Stock has been registered pursuant to Section&nbsp;12(b)&nbsp;of
the 1934 Act, and the Shares have been approved for listing, subject to official notice of issuance, on the New York Stock Exchange (the
 &ldquo;<U>NYSE</U>&rdquo;), and the Company has taken no action designed to, or likely to have the effect of, terminating the registration
of the Common Stock under the 1934 Act or the listing of the Common Stock (including the Shares) on the NYSE, nor has the Company received
any notification that the Commission or the NYSE is contemplating terminating such registration or listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Authorization
of this Agreement</U>. This Agreement has been duly authorized, executed and delivered by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Authorization
and Description of Shares</U>. The Shares have been duly authorized for issuance and sale by the Company pursuant to this Agreement and,
when issued and delivered by the Company pursuant to this Agreement against payment of the consideration set forth in this Agreement,
will be validly issued and fully paid and non-assessable. The issuance of the Shares is not subject to the preemptive or other similar
rights of any securityholder of the Company or any other person or entity. The Common Stock conforms in all material respects to all statements
relating thereto contained in the Registration Statement, the General Disclosure Package and the Prospectus and such statements conform
in all material respects to the rights set forth in the instruments defining the same. No holder of Shares will be subject to personal
liability solely by reason of being such a holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xiii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Registration
Rights</U>. There are no persons with registration rights or other similar rights to have any securities registered for sale pursuant
to the Registration Statement or otherwise registered for sale or sold by the Company under the 1933 Act pursuant to this Agreement, other
than those rights that have been disclosed in the Registration Statement, the General Disclosure Package and the Prospectus and have been
waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xiv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Absence
of Violations, Defaults and Conflicts</U>. The Company is not (A)&nbsp;in violation of its charter, by-laws or similar organizational
document, (B)&nbsp;in default in the performance or observance of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">any obligation, agreement, covenant
or condition contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement
or instrument to which the Company is a party or by which it may be bound or to which any of the properties, assets or operations of
the Company is subject (collectively, &ldquo;<U>Agreements and Instruments</U>&rdquo;), except for such defaults that would not, singly
or in the aggregate, result in a Material Adverse Effect, or (C)&nbsp;in violation of any law, statute, rule, regulation, judgment, order,
writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency (including, without limitation, the
U.S. Food and Drug Administration (the &ldquo;FDA&rdquo;) or the U.S. Centers for Medicare and Medicaid Services) or other authority,
body or agency having jurisdiction over the Company or any of its properties, assets or operations (each, a &ldquo;<U>Governmental Entity</U>&rdquo;),
except for such violations that would not, singly or in the aggregate, result in a Material Adverse Effect. The execution, delivery and
performance of this Agreement and the consummation of the transactions contemplated herein and in the Registration Statement, the General
Disclosure Package and the Prospectus (including the issuance and sale of Shares and the use of the proceeds from the sale thereof as
described therein under the caption &ldquo;<U>Use of Proceeds</U>&rdquo;) and compliance by the Company with its obligations hereunder
have been duly authorized by all requisite action and do not and will not, whether with or without the giving of notice or passage of
time or both, conflict with or constitute a breach of, or default or Repayment Event (as defined below) under, or result in the creation
or imposition of any lien, charge or encumbrance upon any properties, assets or operations of the Company pursuant to, the Agreements
and Instruments (except for such conflicts, breaches, defaults or Repayment Events or liens, charges or encumbrances that would not,
singly or in the aggregate, result in a Material Adverse Effect), nor will such action result in any violation of the provisions of the
charter, by-laws or similar organizational document of the Company or any law, statute, rule, regulation, judgment, order, writ or decree
of any Governmental Entity. As used herein, a &ldquo;Repayment Event&rdquo; means any event or condition which gives the holder of any
note, debenture or other financing instrument (or any person acting on such holder&rsquo;s behalf) the right to require the repurchase,
redemption or repayment of all or a portion of the related financing by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Absence
of Labor Dispute</U>. No labor dispute with the employees of the Company exists or, to the knowledge of the Company, is imminent, and
the Company is not aware of any existing or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers,
customers or contractors, which could, singly or in the aggregate, result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xvi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Absence
of Proceedings</U>. Except as stated in the Registration Statement, the General Disclosure Package and the Prospectus, there is no action,
suit, proceeding, inquiry or investigation before or brought by any Governmental Entity now pending, or, to the knowledge of the Company,
threatened, against or affecting the Company which could, singly or in the aggregate, result in a Material Adverse Effect. The aggregate
of all pending legal or governmental proceedings to which the Company is a party or of which any of its properties, assets or operations
are the subject which are not described in the Registration Statement, the General Disclosure Package and the Prospectus, including ordinary
routine litigation incidental to the business, would not, singly or in the aggregate, result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xvii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Accuracy
of Exhibits</U>. There are no contracts or documents which are required to be described in the Registration Statement, any preliminary
prospectus or the Prospectus or to be filed as exhibits to the Registration Statement which have not been so described and filed as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xviii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Absence
of Further Requirements</U>. No filing with, or authorization, approval, consent, license, order, registration, qualification or decree
of, any Governmental Entity is necessary or required for the Company&rsquo;s due authorization, execution and delivery of, or performance
of its obligations under, this Agreement or for the offering, issuance, sale or delivery of Shares or the consummation of the transactions
contemplated in this Agreement, except such as have been already obtained or as may be required under the 1933 Act, the 1933 Act Regulations,
the rules&nbsp;of the NYSE, the securities laws of any state or non-U.S. jurisdiction or the rules&nbsp;of Financial Industry Regulatory
Authority,&nbsp;Inc. (&ldquo;<U>FINRA</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xix)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Possession
of Licenses and Permits</U>. The Company possesses such permits, licenses, approvals, consents and other authorizations issued by the
appropriate Governmental Entities necessary to conduct the business now operated by it (collectively, &ldquo;Governmental Licenses&rdquo;)
(including, without</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">limitation,
all such Governmental Licenses required by any Governmental Entity engaged in the regulation of clinical registries, clinical trials
or activities related to the business now operated by the Company in such jurisdictions), except where the failure so to possess would
not, singly or in the aggregate, result in a Material Adverse Effect. The Company is in compliance with the terms and conditions of all
Governmental Licenses, except where the failure so to comply would not, singly or in the aggregate, result in a Material Adverse Effect.
All of the Governmental Licenses are valid and in full force and effect, except where the invalidity of such Governmental Licenses or
the failure of such Governmental Licenses to be in full force and effect would not, singly or in the aggregate, result in a Material
Adverse Effect. The Company has not received any notice of proceedings relating to the revocation or modification of any Governmental
Licenses which, if the subject of an unfavorable decision, ruling or finding, could, singly or in the aggregate, result in a Material
Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xx)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Title
to Property</U>. The Company does not own any real property. All of the leases and subleases material to the business of the Company,
and under which the Company holds properties described in the Registration Statement, the General Disclosure Package or the Prospectus,
are in full force and effect, and the Company has not received any notice of any material claim of any sort that has been asserted by
anyone adverse to its rights under any of the leases or subleases mentioned above or affecting or questioning its rights to the continued
possession of the leased or subleased premises under any such lease or sublease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Possession
of Intellectual Property</U>. The Company owns or possesses, has a valid license to, or can acquire on reasonable terms, all patents,
patent applications, statutory invention rights, community designs, invention disclosures, rights in utility models and industrial designs,
licenses, inventions, copyrights (including copyrights in software), intellectual property rights in technology and software, data and
know how (including, without limitation, trade secrets and other unpatented and/or unpatentable proprietary or confidential information,
systems or procedures), trademarks, service marks, trade names, business names, logos, slogans, trade dress, design rights,&nbsp;Internet
domain names, any other designations of source or origin and other intellectual property or proprietary rights (including all registrations
and applications for registration and renewals of, and all goodwill associated with, the foregoing) (collectively, &ldquo;Intellectual
Property&rdquo;) necessary to carry on the business now operated by it and as proposed to be operated as described in the Registration
Statement, the General Disclosure Package and the Prospectus. (a)&nbsp;The Company has not engaged in, nor received any notice or is otherwise
aware of, any infringement, misappropriation or other violation of or conflict with respect to any Intellectual Property of any third
party, (b)&nbsp;there is no pending or threatened action, suit, proceeding or claim regarding the subject matter of the foregoing clause
(a), and (c)&nbsp;the Company is unaware of any facts or circumstances which would form a reasonable basis for any such claim. All Intellectual
Property owned by or exclusively licensed to the Company (such Intellectual Property, the &ldquo;Company Intellectual Property&rdquo;)
is valid, subsisting and enforceable, and free of material defects, including with respect to the filing and prosecution thereof. There
is no pending or threatened action, suit, proceeding or claim by any third party challenging the validity, ownership, registrability,
enforceability or scope of any Company Intellectual Property and the Company is unaware of any facts or circumstances which would form
a reasonable basis for any such claim or render any Company Intellectual Property invalid or inadequate to protect the interest of the
Company therein, and which infringement or conflict, if the subject of an unfavorable decision, ruling or finding, invalidity or inadequacy
could, singly or in the aggregate, result in a Material Adverse Effect. No third party is, to the Company&rsquo;s knowledge, infringing,
misappropriating or otherwise violating any of the Company Intellectual Property and there is no pending or threatened action, suit, proceeding
or claim by the Company against a third party regarding the foregoing. (x)&nbsp;The Company has complied in all material respects with
the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company, (y)&nbsp;the Company has not received
any written notice alleging any noncompliance therewith and is unaware of any facts or circumstances which would form a reasonable basis
for any such claim and (z)&nbsp;all such agreements are in full force and effect. Each Person who is or was an employee or contractor
of the Company and who is, was or is expected to be involved in the creation or development of any Intellectual Property for or on behalf
of the Company has executed a valid written agreement containing an enforceable assignment to the Company all of such Person&rsquo;s rights
in and to such Intellectual Property and, to the Company&rsquo;s knowledge, no employee of the Company is in or has ever been in violation
of any term of any agreement with or covenant to a former employer where the basis of such violation relates to such </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">employee&rsquo;s
employment with the Company or actions undertaken by the employee while employed with the Company. The Company has taken all reasonable
steps necessary to maintain and protect the confidentiality of the material trade secrets and other material confidential Intellectual
Property used in connection with the business of the Company, and the confidentiality of such material trade secrets and material confidential
Intellectual Property has not been compromised or disclosed to or accessed by any third party, except in each case pursuant to appropriate
nondisclosure and confidentiality agreements. No university, military, educational institution, research center, Governmental Entity or
other organization has funded, sponsored or contributed to research and development conducted in connection with the business of the Company
that (i)&nbsp;has any claim of right to, ownership of or other lien on any Company Intellectual Property or (ii)&nbsp;would affect the
proprietary nature of any Company Intellectual Property or restrict the ability of the Company to enforce, license or exclude others from
using any Company Intellectual Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Environmental
Laws</U>. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus or would not, singly or
in the aggregate, result in a Material Adverse Effect, (A)&nbsp;the Company is not in violation of any federal, state, local or foreign
statute, law, rule, regulation, ordinance, code, policy or rule&nbsp;of common law or any judicial or administrative interpretation thereof,
including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the
environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including,
without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes,
toxic substances, hazardous substances, petroleum or petroleum products, asbestos-containing materials or mold (collectively, &ldquo;<U>Hazardous
Materials</U>&rdquo;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous
Materials (collectively, &ldquo;<U>Environmental Laws</U>&rdquo;), (B)&nbsp;the Company has all permits, authorizations and approvals
required under any applicable Environmental Laws and is in compliance with their requirements, (C)&nbsp;there are no pending or, to the
knowledge of the Company, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices
of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company and (D)&nbsp;to the
knowledge of the Company, there are no events or circumstances that would reasonably be expected to form the basis of an order for clean-up
or remediation, or an action, suit or proceeding by any private party or Governmental Entity, against or affecting the Company relating
to Hazardous Materials or any Environmental Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxiii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Accounting
Controls and Disclosure Controls</U>. The Company maintains effective internal control over financial reporting (as defined under Rule&nbsp;13-a15
and Rule&nbsp;15d-15 of the 1934 Act Regulations) and a system of internal accounting controls sufficient to provide reasonable assurances
that: (A)&nbsp;transactions are executed in accordance with management&rsquo;s general or specific authorization; (B)&nbsp;transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets;
(C)&nbsp;access to assets is permitted only in accordance with management&rsquo;s general or specific authorization; (D)&nbsp;the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to
any differences; and (E)&nbsp;the interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration
Statement, the General Disclosure Package and the Prospectus fairly presents in all material respects the required information and is
prepared in accordance with the Commission's rules&nbsp;and guidelines applicable thereto. Except as described in the Registration Statement,
the General Disclosure Package and the Prospectus, since the end of the Company&rsquo;s most recent audited fiscal year, there has been
(1)&nbsp;no material weakness in the Company&rsquo;s internal control over financial reporting (whether or not remediated) and (2)&nbsp;no
change in the Company&rsquo;s internal control over financial reporting that has materially affected, or is reasonably likely to materially
affect, the Company&rsquo;s internal control over financial reporting. The Company maintains an effective system of disclosure controls
and procedures (as defined in Rule&nbsp;13a-15 and Rule&nbsp;15d-15 of the 1934 Act Regulations) that are designed to ensure that the
information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is recorded, processed,
summarized and reported, within the time periods specified in the Commission&rsquo;s rules&nbsp;and forms, and is accumulated and communicated
to the Company&rsquo;s management, including its principal executive officer or officers and principal financial officer or officers,
as appropriate, to allow timely decisions regarding disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxiv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compliance
with the Sarbanes-Oxley Act</U>. There is and has been no failure on the part of the Company or any of the Company&rsquo;s directors or
officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002 and the
rules&nbsp;and regulations promulgated in connection therewith, including, without limitation, Section&nbsp;402 related to loans and Sections
302 and 906 related to certifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Payment
of Taxes</U>. All United States federal income tax returns of the Company required by law to be filed have been filed and all taxes shown
by such returns or otherwise assessed, which are due and payable, have been paid, except assessments against which appeals have been or
will be promptly taken and as to which adequate reserves have been provided. The United States federal income tax returns of the Company
through the fiscal year ended December&nbsp;31, 2021 have been settled and no assessment in connection therewith has been made against
the Company. The Company has filed all other tax returns that are required to have been filed by it pursuant to applicable foreign, state,
local or other law except insofar as the failure to file such returns would not, singly or in the aggregate, result in a Material Adverse
Effect, and has paid all taxes due pursuant to such returns or pursuant to any assessment received by the Company, except for such taxes,
if any, as are being contested in good faith and as to which adequate reserves have been established by the Company. The charges, accruals
and reserves on the books of the Company in respect of any income and corporation tax liability for any years not finally determined are
adequate to meet any assessments or re-assessments for additional income tax for any years not finally determined, except to the extent
of any inadequacy that would not, singly or in the aggregate, result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxvi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Insurance</U>.
The Company carries or is entitled to the benefits of insurance, with financially sound and reputable insurers, in such amounts and covering
such risks as is generally maintained by companies of established repute engaged in the same or similar business, and all such insurance
is in full force and effect. The Company has no reason to believe that it will not be able (A)&nbsp;to renew its existing insurance coverage
as and when such policies expire or (B)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or appropriate
to conduct its business as now conducted and at a cost that would not, singly or in the aggregate, result in a Material Adverse Effect.
The Company has not been denied any insurance coverage which it has sought or for which it has applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxvii)&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Investment
Company Act</U>. The Company is not required, and upon the issuance and sale of the Shares as contemplated herein and the application
of the net proceeds therefrom as described in the Registration Statement, the General Disclosure Package and the Prospectus will not be
required, to register as an &ldquo;investment company&rdquo; under the Investment Company Act of 1940, as amended (the &ldquo;<U>1940
Act</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxviii)&#8239;&#8239;&#8239;&#8239;</FONT><U>Absence
of Manipulation</U>. Neither the Company nor any affiliate of the Company has taken, nor will the Company or any such affiliate take,
directly or indirectly, any action which is designed, or would be expected, to cause or result in, or which constitutes, the stabilization
or manipulation of the price of any security of the Company to facilitate the sale or resale of any Shares or to result in a violation
of Regulation M under the 1934 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxix)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Foreign
Corrupt Practices Act</U>. The Company is not and, to the knowledge of the Company, no director, officer, agent, employee, affiliate or
other person acting on behalf of the Company is aware of or has taken any action, directly or indirectly, that would result in a violation
by such persons of either (A)&nbsp;the Foreign Corrupt Practices Act of 1977, as amended, and the rules&nbsp;and regulations thereunder
(the &ldquo;<U>FCPA</U>&rdquo;), including, without limitation, making use of the mails or any means or instrumentality of interstate
commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property,
gift, promise to give, or authorization of the giving of anything of value to any &ldquo;foreign official&rdquo; (as such term is defined
in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the
FCPA or (B)&nbsp;the U.K. Bribery Act 2010 (the &ldquo;<U>Bribery Act</U>&rdquo;), and the Company and, to the knowledge of the Company,
its other affiliates have conducted their businesses in compliance with the FCPA and the Bribery Act and have instituted and maintain
policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxx)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Money
Laundering Laws</U>. The operations of the Company is and has been conducted at all times in compliance with applicable financial recordkeeping
and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of
all jurisdictions, the rules&nbsp;and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered
or enforced by any Governmental Entity (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;). No action, suit or proceeding by
or before any Governmental Entity involving the Company with respect to the Money Laundering Laws is pending or, to the best knowledge
of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxxi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>OFAC</U>.
The Company is not and, to the knowledge of the Company, no director, officer, agent, employee, affiliate or other person acting on behalf
of the Company is (A)&nbsp;an individual or entity (&ldquo;<U>Person</U>&rdquo;) currently the subject or target of any sanctions administered
or enforced by the United States Government, including, without limitation, the U.S. Department of the Treasury&rsquo;s Office of Foreign
Assets Control, the United Nations Security Council, the European Union, Her Majesty&rsquo;s Treasury, or other relevant sanctions authority
(collectively, &ldquo;<U>Sanctions</U>&rdquo;), or (B)&nbsp;located, organized or resident in a country or territory that is the subject
of Sanctions. The Company will not, directly or indirectly, use the proceeds of the sale of the Shares, or lend, contribute or otherwise
make available such proceeds to any of its joint venture partners or other Persons, to fund any activities of or business with any Person,
or in any country or territory, that, at the time of such funding, is the subject of Sanctions or in any other manner that will result
in a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise)
of Sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxxii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Lending
Relationship</U>. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company (A)&nbsp;does
not have any material lending or other relationship with the Agents or any bank, lending or other affiliate of an Agent and (B)&nbsp;does
not intend to use any of the proceeds from the sale of the Shares to repay any outstanding debt owed to an Agent or any affiliate of an
Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxxiii)&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Statistical
and Market-Related Data</U>. Any statistical and market-related data included in the Registration Statement, the General Disclosure Package
or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate
and, to the extent required, the Company has obtained the written consent to the use of such data from such sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxxiv)&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Commissions</U>. The Company is not a party to any contract, agreement or understanding with any person (other than as contemplated by
this Agreement) that would give rise to a valid claim against the Company or the Agents for a brokerage commission, finder&rsquo;s fee
or like payment in connection with the offering and sale of any Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxxv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Not
an Actively-Traded Security</U>. The Common Stock is not an &ldquo;actively-traded security&rdquo; exempted from the requirements of Rule&nbsp;101
of Regulation M under the 1934 Act by subsection (c)(1)&nbsp;of such rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxxvi)&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Cybersecurity
and Data Protection</U>. (A)&nbsp;To the knowledge of the Company, there has been no security breach or incident, unauthorized access
or disclosure, or other compromise of or relating to the Company information technology and computer systems, networks, hardware, software,
data and databases (including the data and information of its patients, customers, employees, suppliers, vendors and any third party data
maintained, processed or stored by the Company, and any such data processed or stored by third parties on behalf of the Company), equipment
or technology (collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;); (B)&nbsp;the Company has not been notified of, and has no knowledge
of any event or condition that could result in, any security breach or incident, unauthorized access or disclosure of or other compromise
to its IT Systems and Data; and (C)&nbsp;the Company has implemented appropriate controls, policies, procedures, and technological safeguards
to maintain and protect the integrity, continuous operation, redundancy, disaster recovery and security of its IT Systems and Data reasonably
consistent with industry standards and practices, or as required by applicable data protection laws, healthcare laws and regulatory standards.
The IT Systems and Data are adequate and operational for, in accordance with their documentation and functional specifications, the business
of the Company as now operated by it and as currently proposed to be operated as described in the Registration Statement, the General
Disclosure Package and the Prospectus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The Company is in compliance in all
material respects with all applicable laws or statutes and all judgments, orders, rules&nbsp;and regulations of any court or arbitrator
or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of the IT
Systems and Data, including the collection, use, transfer, processing, disposal, disclosure, handling, storage and analysis of personally
identifiable information, protected health information, consumer information and other confidential information of the Company and any
third parties in their possession (&ldquo;<U>Sensitive Company Data</U>&rdquo;), and the protection of such IT Systems and Data and Sensitive
Company Data from unauthorized use, access, misappropriation or modification. The Company has taken reasonable steps necessary to maintain
the confidentiality of the Sensitive Company Data. The Company has not received any written notice, claim, complaint, demand or letter
from any Person or Governmental Entity in respect of its business under applicable data security and data protection laws and regulations
and industry standards regarding misuse, loss, unauthorized destruction or unauthorized disclosure of any Sensitive Company Data. To
the knowledge of the Company, there has been no unauthorized or illegal use of or access to any Sensitive Company Data by any third party.
The Company has not been required to notify any individual, Governmental Entity or data protection authority of any information security
breach, compromise or incident involving Sensitive Company Data and are not the subject of any inquiry or investigation by any Governmental
Entity or data protection authority regarding any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxxvii)&#8239;&#8239;&#8239;&#8239;</FONT><U>ERISA
Compliance</U>. The Company and any &ldquo;Employee Benefit Plan&rdquo; (within the meaning of Section&nbsp;3(3)&nbsp;of the Employee
Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &ldquo;ERISA&rdquo;))
for which the Company or its &ldquo;ERISA Affiliates&rdquo; (as defined below) would have any liability (each, a &ldquo;Plan&rdquo;) are
in compliance with ERISA and each Plan has been established and maintained in compliance with its terms and the requirements of any applicable
statutes, orders, rules&nbsp;and regulations, including but not limited to, ERISA and the Internal Revenue Code of 1986, as amended, and
the regulations and published interpretations thereunder (the &ldquo;Code&rdquo;). No &ldquo;reportable event&rdquo; (as defined under
ERISA) has occurred or is reasonably expected to occur with respect to any Plan. No Plan, if such Plan were terminated, would have any
 &ldquo;amount of unfunded benefit liabilities&rdquo; (as defined under ERISA). Neither the Company nor any of its ERISA Affiliates has
incurred or reasonably expects to incur any obligation or liability under (i)&nbsp;Title IV of ERISA with respect to termination of, or
withdrawal from, any Plan, (ii)&nbsp;Sections 412 and 430, 4971, 4975 or 4980B of the Code or (iii)&nbsp;Sections 302 and 303, 406, 4063
and 4064 of ERISA. Each Plan that is intended to be qualified under Section&nbsp;401(a)&nbsp;of the Code is so qualified and nothing has
occurred, whether by action or failure to act, which would cause the loss of such qualification. There is no pending audit or investigation
by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty Corporation or any other governmental agency
or any foreign regulatory agency with respect to any Plan that could reasonably be expected to result in liability to the Company. The
Company does not have any &ldquo;accumulated postretirement benefit obligations&rdquo; (within the meaning of Statement of Financial Accounting
Standards 106). &ldquo;ERISA Affiliate&rdquo; means, with respect to the Company, any member of any group of organizations described in
Sections 414(b), (c), (m)&nbsp;or (o)&nbsp;of the Code of which the Company is a member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(xxxviii)&#8239;&#8239;&#8239;<U>Regulatory
Matters</U>. (i)&nbsp;The Company has not received any FDA Form&nbsp;483, written notice of adverse filing, warning letter, untitled letter
or other correspondence or notice from the FDA or other relevant regulatory authorities, or any other court or arbitrator or federal,
state, local or foreign governmental or regulatory authority, alleging or asserting material noncompliance with the Federal Food, Drug
and Cosmetic Act (21 U.S.C. &sect; 301 et seq.), as amended, and the regulations promulgated thereunder (the &ldquo;FFDCA&rdquo;), the
Anti-Kickback Statute (42 U.S.C. Section&nbsp;1320a-7b(b)), the Civil Monetary Penalties Law (42 U.S.C. &sect; 1320a-7a), the Physician
Payment Sunshine Act (42 U.S.C. &sect; 1320a-7h), the Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal False
Claims Law (42 U.S.C. &sect; 1320a-7b(a)), all criminal laws relating to health care fraud and abuse, including but not limited to 18
U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability
Act of 1996 (&ldquo;<U>HIPAA</U>&rdquo;) (42 U.S.C. Section&nbsp;1320d et seq.), the exclusion laws (42 U.S.C. &sect; 1320a-7), HIPAA,
as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.), Medicare
(Title XVIII of the Social Security Act), Medicaid (Title XIX of the Social Security Act), and any and all other similar state, local,
federal or foreign health care laws and the regulations promulgated pursuant to such laws, including all laws and regulations applicable
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">to
ownership, testing, development, manufacture, packaging, processing, use, distribution, storage, import, export or disposal of the Company&rsquo;s
product candidates, each as amended from time to time (collectively, &ldquo;Health Care Laws&rdquo;); (ii)&nbsp;the Company is and has
been in compliance in all material respects with applicable Health Care Laws; (iii)&nbsp;the Company has not engaged in activities which
are, as applicable, cause for false claims liability, civil penalties or mandatory or permissive exclusion from Medicare, Medicaid, or
any other state health care program or federal health care program; (iv)&nbsp;the Company has not received written notice of any claim,
action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or U.S. or non-U.S.
federal, national, state, local or other governmental or regulatory authority, governmental or regulatory agency or body, court, arbitrator
or self-regulatory organization (each, a &ldquo;Governmental Authority&rdquo;) or third party alleging that any product operation or
activity is in violation of any Health Care Laws and, to the Company&rsquo;s knowledge, no such claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action is threatened; (v)&nbsp;the Company has filed, obtained, maintained or submitted
all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by applicable
Health Care Laws, and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or
amendments were complete, correct and not misleading on the date filed (or were corrected or supplemented by a subsequent submission);
(vi)&nbsp;neither the Company nor its directors, officers, employees or, to the best of its knowledge, agents are or have been debarred,
suspended or excluded, or has been convicted of any crime or engaged in any conduct that would result in a debarment, suspension or exclusion
from any federal or state government health care program, human research study, clinical trial, or clinical registry, or to the knowledge
of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected
to result in debarment, suspension, or exclusion; and (vii)&nbsp;the Company is not a party to and the Company does not have any ongoing
reporting obligations pursuant to, any court order, injunction, ruling, or consent or party to any judgment, decree or settlement, including,
without limitation, any corporate integrity agreements, deferred prosecution agreements, certification of compliance agreement, monitoring
agreements, consent decrees, settlement orders, plans of correction or similar agreements with or civil monetary penalties imposed by
an Governmental Authority, in each case under or in any way relating to Health Care Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xxxix)&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Preclinical
Studies and Clinical Trials</U>. The preclinical studies and clinical trials conducted by, on behalf of or sponsored by the Company, or
in which the Company has participated, that are described in the Registration Statement, the General Disclosure Package or the Prospectus,
or the results of which are referred to in the Registration Statement, the General Disclosure Package or the Prospectus, as applicable,
were, and if still pending, are being conducted in all respects in accordance with the experimental protocols established for each study
or trial, as well as any conditions of approval and policies imposed by any institutional review board, ethics review board or committee
responsible for the oversight of such studies and trials, all accepted professional and scientific standards, and all applicable local,
state and federal laws, rules&nbsp;and regulations of the FDA and comparable drug regulatory agencies outside of the United States to
which they are subject (such institutional review boards, ethics review boards, committees, the FDA or any comparable regulatory agencies,
collectively, the &ldquo;Regulatory Authorities&rdquo;) and all other applicable Health Care Laws; the descriptions in the Registration
Statement, the General Disclosure Package or the Prospectus of the results of such studies and trials do not contain any misstatement
of a material fact or omit to state a material fact necessary to make such statements not misleading, and fairly present the data derived
from such studies or trials; the Company has no knowledge of any other studies or trials not described in the Registration Statement,
the General Disclosure Package and the Prospectus, the results of which are inconsistent with or reasonably call into question the results
described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus when viewed in the context in
which such results are described and the current state of development; the Company has not received any written notice, correspondence
or other communications from the Regulatory Authorities requiring or threatening (i)&nbsp;the termination or suspension or clinical hold
of any research studies, clinical trials or clinical registries conducted by or on behalf of, or sponsored by, the Company or in which
the Company has participated, or (ii)&nbsp;the material modification of any studies or trials that would cause them to differ from their
descriptions in the Registration Statement, the General Disclosure Package and the Prospectus, other than ordinary course communications
with respect to modifications in connection with the design and implementation of such studies or trials, and, to the </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Company&rsquo;s
knowledge, there are no reasonable grounds for the same. There has not been any violation of applicable law or regulation by the Company
in its product development, submissions or reports to any regulatory authority that could be expected to require investigation, corrective
action or enforcement action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xl)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Health
Care Products Manufacturing</U>. The manufacture of the Company&rsquo;s product candidates by or on behalf of the Company is being conducted
in compliance in all material respects with all applicable Health Care Laws, including, without limitation, the FDA&rsquo;s current good
manufacturing practice regulations at 21 CFR Part&nbsp;820, and, to the extent applicable, the respective counterparts thereof promulgated
by governmental authorities in countries outside the United States. The Company has not had any manufacturing site (whether Company-owned,
or that of a third party manufacturer for the Company&rsquo;s product candidates) subject to a Governmental Authority (including FDA)
shutdown or import or export prohibition, nor received any FDA or other Governmental Authority &ldquo;warning letters,&rdquo; or &ldquo;untitled
letters&rdquo; alleging or asserting material noncompliance with any applicable Health Care Laws, requests to make material changes to
the Company&rsquo;s product candidates, processes or operations, or similar correspondence or notice from the FDA or other Governmental
Authority alleging or asserting material noncompliance with any applicable Health Care Laws, other than those that have been satisfactorily
addressed and/or closed with the FDA or other Governmental Authority. To the knowledge of the Company, neither the FDA nor any other Governmental
Authority is considering such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xli)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Safety Notices</U>. (i)&nbsp;There have been no recalls, field notifications, field corrections, market withdrawals or replacements, warnings,
 &ldquo;dear doctor&rdquo; letters, investigator notices, safety alerts or other notices of action relating to an alleged lack of safety,
efficacy, or regulatory compliance of the Company&rsquo;s product candidates (&ldquo;<U>Safety Notices</U>&rdquo;) and (ii)&nbsp;there
are no facts that would be reasonably likely to result in (x)&nbsp;a Safety Notice with respect to the Company&rsquo;s product candidates,
(y)&nbsp;a change in labeling of any of the Company&rsquo;s product candidates, or (z)&nbsp;a termination or suspension of marketing or
testing of any of the Company&rsquo;s product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any certificate signed by any officer or other
authorized signatory of the Company and delivered to the Agents or to counsel for the Agents shall be deemed a representation and warranty
by the Company to the Agents as to the matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;2.
</FONT><U>Sale and Delivery of Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Subject
to the terms and conditions set forth herein, the Company agrees to issue and sell Shares through the applicable Agents acting as sales
agent or directly to the applicable Agents acting as principal from time to time. Sales of the Shares, if any, through an Agent acting
as sales agent or directly to an Agent acting as principal will be made by means of transactions that are deemed to be &ldquo;at-the-market&rdquo;
offerings as defined in Rule&nbsp;415 under the 1933 Act, including block trades, ordinary brokers&rsquo; transactions on the NYSE or
otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Shares are to be sold to an Agent on an agented basis on any day (other than a day on which the NYSE is scheduled to close prior to its
regular weekday closing time) (each, a &ldquo;<U>Trading Day</U>&rdquo;) on which (i)&nbsp;the Company has instructed such Agent to make
such sales and (ii)&nbsp;the Company has satisfied its covenants and conditions specified in Sections 4 and 5 hereof. On any Trading Day,
the Company may sell Shares through only one Agent and, if it determines to do so, shall instruct the applicable Agent by telephone (confirmed
promptly by telecopy or email, which confirmation will be promptly acknowledged by such Agent) as to the maximum number of Shares to be
sold on such Trading Day and the minimum price per Share at which such Shares may be sold. Subject to the terms and conditions specified
herein (including, without limitation, the accuracy of the representations and warranties of the Company and the performance by the Company
of its covenants and other obligations, contained herein and the satisfaction of the additional conditions specified in Section&nbsp;5
hereof), such Agent shall use its commercially reasonable efforts, consistent with its normal trading and sales practices and applicable
law and regulations, to sell all of the Shares so designated by the Company as sales agent in accordance with such instruction. On any
Trading Day, the Company shall give at least one business day&rsquo;s prior written notice by telecopy or email to the Agents as to any
change of the Agent through whom sales of Shares as sales agent will be made. For the avoidance of doubt, the foregoing limitation shall
not apply to sales solely to employees or security holders of the Company or to a trustee or other person acquiring Shares for the accounts
of such persons in</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"> which either BofA or ThinkEquity is acting for the Company in a capacity other than as Agent under this Agreement.
The Company and the Agents each acknowledge and agree that (A)&nbsp;there can be no assurance that any Agent will be successful in selling
any Shares and (B)&nbsp;the Agents will not incur any liability or obligation to the Company if they fail to sell Shares for any reason
other than a failure to use their respective commercially reasonable efforts, consistent with its normal trading and sales practices and
applicable law and regulations, to sell such Shares as required by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company or the Agent through whom the sale of Shares are to be made as sales agent on any Trading Day may, upon notice to the other party
hereto by telephone (confirmed promptly by telecopy or email, which confirmation will be promptly acknowledged by the receiving party),
suspend the offering of Shares with respect to which such Agent is acting as sales agent for any reason and at any time; <U>provided</U>,
<U>however</U>, that such suspension shall not affect or impair the parties&rsquo; respective obligations with respect to the Shares sold,
or with respect to Shares that the Company has agreed to sell, hereunder prior to the giving of such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
gross sales price of any Shares sold pursuant to this Agreement by the applicable Agent acting as sales agent of the Company shall be
equal to, in the discretion of such Agent but subject to the specific instructions of the Company, the market price prevailing at the
time of sale for the Shares sold by such Agent on the NYSE or otherwise, at prices related to prevailing market prices or at negotiated
prices. The compensation payable to an Agent for sales of Shares with respect to which such Agent acts as sales agent shall be equal to
2.0% of the gross sales price for such Shares. The remaining proceeds, after further deduction for any transaction fees, transfer taxes
or similar taxes or fees imposed by any Governmental Entity or self-regulatory organization in respect of such sales, shall constitute
the net proceeds to the Company for such sales (the &ldquo;<U>Net Proceeds</U>&rdquo;). The applicable Agent shall notify the Company
as promptly as practicable if any deduction referenced in the preceding sentence will be made. Notwithstanding the foregoing, in the event
the Company engages an Agent as sales agent for the sale of Shares that would constitute a &ldquo;distribution&rdquo; within the meaning
of Rule&nbsp;100 of Regulation M under the 1934 Act, the Company and such Agent will agree to compensation for such Agent that is customary
for such sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
acting as sales agent hereunder, the applicable Agent shall provide written confirmation to the Company following the close of trading
on the NYSE on each Trading Day on which Shares are sold under this Agreement setting forth (i)&nbsp;the number of Shares sold on such
day, (ii)&nbsp;the aggregate gross sales proceeds of the Shares, (iii)&nbsp;the aggregate Net Proceeds to the Company and (iv)&nbsp;the
aggregate compensation payable by the Company to such Agent with respect to such sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Under
no circumstances shall the aggregate gross sales price or number, as the case may be, of Shares offered or sold pursuant to this Agreement,
or which are the subject of instructions to an Agent as sales agent pursuant to Section&nbsp;2(b)&nbsp;hereof, exceed the aggregate gross
sales price or number, as the case may be, of Shares (i)&nbsp;referred to in the preamble paragraph of this Agreement, as reduced by prior
sales of Shares under this Agreement, (ii)&nbsp;available for sale under the Registration Statement or (iii)&nbsp;duly authorized from
time to time to be issued and sold under this Agreement by the Company or approved for listing on the NYSE, and, in each case referred
to in clause (ii)&nbsp;and (iii), notified to the Agents in writing. In addition, under no circumstances shall any Shares with respect
to which the Agent acts as sales agent be offered or sold, or be the subject of instructions to an Agent as sales agent pursuant to Section&nbsp;2(b)&nbsp;hereof,
at a price lower than the minimum price therefor duly authorized from time to time by the Company and notified to the Agents in writing.
The Agents shall have no responsibility for maintaining records with respect to Shares available for sale under the Registration Statement
or for determining the aggregate gross sales price, number or minimum price of Shares duly authorized by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Settlement
for sales of Shares will occur on the second business day that is also a Trading Day following the trade date on which such sales are
made, unless another date shall be agreed to in writing by the Company and the applicable Agents (each such day, a &ldquo;<U>Settlement
Date</U>&rdquo;). On each Settlement Date for the sale of Shares through an Agent as sales agent, such Shares shall be delivered by the
Company to such Agent in book-entry form to such Agent&rsquo;s account at The Depository Trust Company against payment by such Agent of
the Net Proceeds from the sale of such Shares in same day funds delivered to an account designated by the Company. If the Company shall
default on its obligation to deliver Shares through an Agent as sales agent on any Settlement Date, the Company shall (i)&nbsp;indemnify
and hold such Agent harmless against any loss, claim or damage arising from or as a result of such default by the Company and (ii)&nbsp;pay
such Agent any commission to which it would otherwise be entitled absent such default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
any other provision of this Agreement, the Company shall not offer or sell, or instruct an Agent to offer or sell, any Shares through
an Agent as sales agent (and, by notice to the Agents given by telephone (confirmed promptly by telecopy or email), shall cancel any instructions
for any such offer or sale of any Shares prior to the commencement of the periods referenced below), and the Agents shall not be obligated
to make any such offer or sale of Shares, (i)&nbsp;during any period in which the Company is, or could be deemed to be, in possession
of material non-public information or (ii)&nbsp;except as provided in Section&nbsp;2(i)&nbsp;hereof, at any time during the period commencing
on the 10<SUP>th</SUP> business day prior to the time the Company issues a press release containing, or shall otherwise publicly announce,
its earnings, revenues or other operating results for a fiscal period or periods (each, an &ldquo;<U>Earnings Announcement</U>&rdquo;)
through and including the time that is 24 hours after the time that the Company files a Quarterly Report on Form&nbsp;10-Q or an Annual
Report on Form&nbsp;10-K (a &ldquo;<U>Filing Time</U>&rdquo;) that includes financial statements as of and for the same fiscal period
or periods, as the case may be, covered by such Earnings Announcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
clause (ii)&nbsp;of Section&nbsp;2(h)&nbsp;hereof, if the Company wishes to offer or sell Shares to an Agent as sales agent at any time
during the period from and including an Earnings Announcement through and including the corresponding Filing Time, the Company shall first
(i)&nbsp;prepare and deliver to such Agent (with a copy to counsel for the Agents) a Current Report on Form&nbsp;8-K that includes substantially
the same financial and related information (together with management&rsquo;s discussion and analysis thereof) that was included in such
Earnings Announcement (other than any earnings projections and similar forward-looking data and officers&rsquo; quotations) (each, an
 &ldquo;<U>Earnings 8-K</U>&rdquo;), in form and substance reasonably satisfactory to such Agent, and, prior to its filing, obtain the
written consent of such Agent to such filing (which consent shall not be unreasonably withheld), (ii)&nbsp;provide such Agent with the
officers&rsquo; certificate, opinions and letters of counsel and accountants&rsquo; letter specified in Section&nbsp;3(o), (p)&nbsp;and
(q), respectively, hereof, (iii)&nbsp;afford such Agent the opportunity to conduct a due diligence review in accordance with Section&nbsp;3(u)&nbsp;hereof
prior to filing such Earnings 8-K and (iv)&nbsp;file such Earnings 8-K with the Commission. For purposes of clarity, the parties hereto
agree that (A)&nbsp;the delivery of any officers&rsquo; certificate, opinion or letter of counsel or accountants&rsquo; letter pursuant
to this Section&nbsp;2(i)&nbsp;shall not relieve the Company from any of its obligations under this Agreement with respect to any Quarterly
Report on Form&nbsp;10-Q or Annual Report on Form&nbsp;10-K, as the case may be, including, without limitation, the obligation to deliver
officers&rsquo; certificates, opinions and letters of counsel and accountants&rsquo; letters as provided in Section&nbsp;3(o), (p)&nbsp;and
(q), respectively, hereof, and (B)&nbsp;this Section&nbsp;2(i)&nbsp;shall in no way affect or limit the operation of clause (i)&nbsp;of
Section&nbsp;2(h)&nbsp;hereof, which shall have independent application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Agents shall not have any obligation to purchase Shares as principal, whether from the Company or otherwise, unless the Company and the
applicable Agents agree as set forth below. Shares purchased from the Company by the applicable Agents, individually or in a syndicate,
as principal shall be made in accordance with terms agreed upon between such Agents and the Company as evidenced by a Terms Agreement.
The applicable Agents&rsquo; commitment to purchase Shares from the Company as principal shall be deemed to have been made on the basis
of the accuracy of the representations and warranties of the Company, and performance by the Company of its covenants and other obligations,
herein contained and shall be subject to the terms and conditions herein set forth. At the time of each Terms Agreement, the applicable
Agents shall specify the requirements, if any, for the officers&rsquo; certificate, opinions and letters of counsel and accountants&rsquo;
letter pursuant to Section&nbsp;3(o), (p)&nbsp;and (q), respectively, hereof. In the event of a conflict between the terms of this Agreement
and a Terms Agreement, the terms of such Terms Agreement shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;3.
</FONT><U>Covenants.</U> The Company agrees with the Agents:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Compliance
with Securities Regulations and Commission Requests</I>. The Company, subject to Section&nbsp;3(b)&nbsp;and 3(c)&nbsp;hereof, will comply
with the requirements of Rule&nbsp;430B, and will promptly notify the Agents, and confirm the notice in writing, (i)&nbsp;when any post-effective
amendment to the Registration Statement or any new registration statement relating to the Shares shall become effective or any amendment
or supplement to the Prospectus shall have been filed (other than an amendment or supplement providing solely for the determination of
the terms of an offering of securities unless related to an offering of Shares, as to which the Company will only be obligated to notify
the applicable Agents), (ii)&nbsp;of the receipt of any comments from the Commission, (iii)&nbsp;of any request by the Commission for
any amendment to the Registration Statement or any amendment or supplement to the Prospectus, including any document incorporated by reference
therein, or for additional information, (iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of
the Registration Statement or any </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">post-effective amendment thereto or any notice
of objection to the use of the Registration Statement or any post-effective amendment thereto pursuant to Rule&nbsp;401(g)(1)&nbsp;or
of the issuance of any order preventing or suspending the use of any preliminary prospectus or the Prospectus or any amendment or supplement
thereto, or of the suspension of the qualification of any Shares for offering or sale in any jurisdiction, or of the initiation or threatening
of any proceedings for any of such purposes or of any examination pursuant to Section&nbsp;8(d)&nbsp;or 8(e)&nbsp;of the 1933 Act concerning
the Registration Statement and (v)&nbsp;if the Company becomes the subject of a proceeding under Section&nbsp;8A of the 1933 Act in connection
with any offering of Shares. In connection with a Terms Agreement, the Company will prepare and file with the Commission, subject to
Section&nbsp;3(c)&nbsp;hereof, a pricing supplement with respect to the offer and sale of Shares covered by such Terms Agreement. The
Company will effect all filings required under Rule&nbsp;424(b), in the manner and within the time period required by Rule&nbsp;424(b)&nbsp;(without
reliance on Rule&nbsp;424(b)(8)), and will take such steps as it deems necessary to ascertain promptly whether the form of prospectus
transmitted for filing under Rule&nbsp;424(b)&nbsp;was received for filing by the Commission and, in the event that it was not, it will
promptly file such prospectus. The Company will make every reasonable effort to prevent the issuance of any stop, prevention or suspension
order and, if any such order is issued, to obtain the lifting thereof as soon as practicable. In the event of any issuance of a notice
of objection, by the Commission, the Company shall take all necessary action to permit offers and sales of Shares by or through the Agents,
including, without limitation, amending the Registration Statement or filing a new shelf registration statement relating thereto. The
Company shall pay the required Commission filing fees relating to the Shares prior to the time the initial Prospectus Supplement is filed
with the Commission or the time any subsequent Prospectus Supplement that increases gross offering price or number of Shares that may
offered and sold under this Agreement from that referenced in the immediately preceding Prospectus Supplement filed with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Continued
Compliance with Securities Laws</I>. The Company will comply with the 1933 Act, the 1933 Act Regulations, the 1934 Act and the 1934 Act
Regulations so as to permit the completion of sales of Shares as contemplated in this Agreement and in the Registration Statement, the
General Disclosure Package and the Prospectus. If any event shall occur or condition shall exist as a result of which it is necessary,
in the opinion of counsel for the Agents or counsel to the Company, to (i)&nbsp;amend the Registration Statement in order that the Registration
Statement will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
to make the statements therein not misleading, (ii)&nbsp;amend or supplement the General Disclosure Package or the Prospectus in order
that the General Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or
omit to state a material fact necessary in order to make the statements therein not misleading in the light of the circumstances existing
at the time it is delivered to a purchaser or (iii)&nbsp;amend the Registration Statement or amend or supplement the General Disclosure
Package or the Prospectus, as the case may be, including, without limitation, the filing of any document incorporated by reference therein,
in order to comply with the requirements of the 1933 Act, the 1933 Act Regulations, the 1934 Act or the 1934 Act Regulations, the Company
will promptly (A)&nbsp;give the Agents or, in the case of an offer and sale of Shares to the applicable Agents as principal, such Agents
written notice of such event or condition, (B)&nbsp;prepare any amendment or supplement as may be necessary to correct such statement
or omission or to comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Agents
or such Agents, as the case may be, with copies of any such amendment or supplement and (C)&nbsp;file with the Commission any such amendment
or supplement and use its commercially reasonable efforts to have any amendment to the Registration Statement declared effective by the
Commission as soon as possible if the Company is no longer eligible to file an automatic shelf registration statement; provided, however,
that the Company shall not file or use any such amendment or supplement to which the Agents or such Agents, as the case may be, or counsel
for the Agents shall reasonably object.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Filing
or Use of Amendments and Supplements</I>. The Company will give the Agents or, in the case of an offer and sale of Shares to the applicable
Agents as principal, such Agents written notice of its intention to file or use (i)&nbsp;any amendment to the Registration Statement or
any amendment or supplement to the General Disclosure Package or the Prospectus (other than an amendment or supplement thereto relating
solely to the offering of securities unless related to an offering of Shares), whether pursuant to the 1933 Act, the 1934 Act or otherwise,
or (ii)&nbsp;any new Prospectus Supplement that includes information in addition to the information referred to in Section&nbsp;3(n)&nbsp;hereof
or (iii)&nbsp;a pricing supplement disclosing the offer and sale of Shares covered by a Terms Agreement, will furnish the Agents or such
Agents, as the case may be, with copies of any such document a reasonable amount of time prior to such proposed filing or use, as the
case may be, and will not file or use any such document to which the Agents or such Agents, as the case may be, or counsel for the Agents
shall reasonably object.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Delivery
of Registration Statements</I>. The Company has furnished or will deliver to the Agents and counsel for the Agents, without charge, signed
copies of the Registration Statement as originally filed and each amendment thereto (including exhibits filed therewith or incorporated
by reference therein and documents incorporated or deemed to be incorporated by reference therein) and signed copies of all consents and
certificates of experts; provided, however that the Company shall not be required to furnish any document to the Agents or their counsel
to the extent such document is available on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Delivery
of Prospectuses</I>. The Company will furnish to the Agents or, in the case of an offer and sale of Shares to the applicable Agents as
principal, such Agents, without charge, upon execution of this Agreement and thereafter during the period in which a prospectus is (or,
but for the exception afforded by Rule&nbsp;172 of the 1933 Act Regulations (&ldquo;<U>Rule&nbsp;172</U>&rdquo;), would be) required by
the 1933 Act to be delivered in connection with any offer or sale of Shares, such number of copies of the Prospectus (as amended or supplemented)
as the Agents or such Agents, as the case may be, may reasonably request. The Company will also furnish, upon request of the Agents or
such Agents, as the case may be, copies of the Prospectus (as amended or supplemented) to each exchange or market on which sales of Shares
were made as may be required by the rules&nbsp;and regulations of such exchange or market. Notwithstanding the foregoing, the Company
shall not be required to furnish any document under this section to the Agents or their counsel to the extent such document is available
on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Reporting
Requirements</I>. The Company, during the period in which a prospectus is (or, but for the exception afforded by Rule&nbsp;172, would
be) required by the 1933 Act to be delivered in connection with any offer or sale of Shares, will file all documents required to be filed
with the Commission pursuant to the 1934 Act within the time periods prescribed by, and meeting the requirements of, the 1934 Act and
the 1934 Act Regulations. Additionally, the Company shall report the use of the net proceeds from the sale of any Shares as may be required
under the 1933 Act and the 1933 Act Regulations, including, if applicable, Rule&nbsp;463 of the 1933 Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Blue
Sky Qualifications</I>. The Company will use commercially reasonable efforts, in cooperation with the Agents or, in the case of an offer
and sale of Shares to the applicable Agents as principal, such Agents to qualify the Shares for offering and sale under the applicable
securities laws of such states and non-U.S. jurisdictions as the Agents or such Agents, as the case may be, may, from time to time, designate
and to maintain such qualifications in effect so long as required to complete the sale of the Shares contemplated by this Agreement; provided,
however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation
or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing
business in any jurisdiction in which it is not otherwise so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Earnings
Statement</I>. The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to make generally available
to its securityholders as soon as practicable an earnings statement for the purposes of, and to provide to the Agents the benefits contemplated
by, the last paragraph of Section&nbsp;11(a)&nbsp;of the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Use
of Proceeds</I>. The Company will use the net proceeds received by it from the sale of the Shares pursuant to this Agreement in the manner
specified in the Registration Statement, the General Disclosure Package and the Prospectus under &ldquo;Use of Proceeds.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Listing</I>.
The Company will use its reasonable best efforts to effect and maintain the listing of the Shares on, and satisfy the requirements of,
the NYSE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Notice
of Certain Actions</I>. The Company will not, without the prior written consent of the Agents, unless it gives the Agents at least five
business days&rsquo; prior written notice, (i)&nbsp;directly or indirectly offer, pledge, sell, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose
of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock or file any
registration statement under the 1933 Act with respect to any of the foregoing or (ii)&nbsp;enter into any swap or any other agreement
or transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Common Stock,
whether any such swap, agreement or transaction described in clause (i)&nbsp;or (ii)&nbsp;above is to be settled by delivery of Common
Stock or such other securities, in cash or otherwise. The foregoing sentence shall not apply to (A)&nbsp;the Shares to be sold hereunder,
(B)&nbsp;any shares of Common Stock issued by the Company upon the exercise of </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">an option or warrant or the conversion of a security outstanding
on the date hereof and referred to in the Registration Statement, the General Disclosure Package and the Prospectus, (C)&nbsp;any shares
of Common Stock issued or options to purchase Common Stock granted pursuant to existing employee benefit plans of the Company referred
to in the Registration Statement, the General Disclosure Package and the Prospectus or (D)&nbsp;any shares of Common Stock issued pursuant
to any non-employee director stock plan or dividend reinvestment plan referred to in the Registration Statement, the General Disclosure
Package and the Prospectus. Upon receipt of any written notice contemplated above, an Agent may suspend its activity under this Agreement
for such period of time as deemed appropriate by such Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Issuer
Free Writing Prospectuses</I>. The Company agrees that, unless it obtains the prior written consent of the applicable Agents, it will
not make any offer relating to the Shares that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a
 &ldquo;free writing prospectus,&rdquo; or a portion thereof, required to be filed by the Company with the Commission or retained by the
Company under Rule&nbsp;433. The Company represents that it has treated or agrees that it will treat each such free writing prospectus
consented to by the applicable Agents as an &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule&nbsp;433, and that it will
comply with the applicable requirements of Rule&nbsp;433 with respect thereto, including timely filing with the Commission where required,
legending and record keeping. If at any time following the issuance of an Issuer Free Writing Prospectus any event shall occur or condition
shall exist as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the
Registration Statement, any preliminary prospectus or the Prospectus or included or would include an untrue statement of a material fact
or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
existing at that subsequent time, not misleading, the Company will promptly notify the applicable Agents and will promptly amend or supplement,
at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>No
Stabilization or Manipulation</I>. The Company agrees that neither it nor any affiliate of the Company will take, directly or indirectly,
any action which is designed, or would be expected, to cause or result in, or which constitutes, the stabilization or manipulation of
the price of any security of the Company to facilitate the sale or resale of any Shares or to result in a violation of Regulation M under
the 1934 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Update
of Activity under this Agreement</I>. The Company shall disclose (i)&nbsp;in each Annual Report on Form&nbsp;10-K or Quarterly Report
on Form&nbsp;10-Q filed by the Company in respect of any fiscal quarterly period (which, in the case of an Annual Report on Form&nbsp;10-K,
would mean the last quarterly period of the fiscal year) in which sales of Shares were made by or through an Agent under this Agreement
(each date on which any such document or amendment thereto is filed, a &ldquo;<U>Company Periodic Report Date</U>&rdquo;), or (ii)&nbsp;to
the extent required by applicable law and/or interpretations of the Commission, in Prospectus Supplements for each such fiscal quarterly
period, the number of Shares sold by or through the Agents under this Agreement during such fiscal quarterly period and the net proceeds
received by the Company and the aggregate compensation paid by the Company to the Agents with respect to such sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Delivery
of Future Officers&rsquo; Certificates</I>. Upon commencement of the offering of Shares under this Agreement, (A)&nbsp;each time Shares
are delivered to the applicable Agents as principal on a Settlement Date, (B)&nbsp;promptly after each (i)&nbsp;date on which the Registration
Statement shall be amended or a new registration statement relating to the Shares shall become effective or the Prospectus shall be amended
or supplemented (other than (1)&nbsp;by an amendment or supplement providing solely for the determination of the terms of securities,
including the Shares, (2)&nbsp;in connection with the filing of a Prospectus Supplement that contains solely the information referred
to in Section&nbsp;3(n)&nbsp;hereof, or (3)&nbsp;in connection with the filing of any Current Report on Form&nbsp;8-K (other than an Earnings
8-K and any other Current Report on Form&nbsp;8-K which contains financial statements, supporting schedules or other financial data, including
any Current Report on Form&nbsp;8-K under Item 2.02 of such form that is considered &ldquo;filed&rdquo; under the 1934 Act) (each such
date, a &ldquo;<U>Registration Statement Amendment Date</U>&rdquo;), (ii)&nbsp;date on which an Earnings 8-K shall be filed with the Commission
as contemplated by Section&nbsp;2(i)&nbsp;hereof (a &ldquo;<U>Company Earnings Report Date</U>&rdquo;) and (iii)&nbsp;Company Periodic
Report Date, and (C)&nbsp;promptly after each reasonable request by the Agents (each date of any such request by the Agents, a &ldquo;<U>Request
Date</U>&rdquo;), the Company will furnish or cause to be furnished to the Agents or, in the case of clause (A)&nbsp;above, the applicable
Agents an officers&rsquo; certificate, dated such Settlement Date, such Registration Statement Amendment Date, such Company Earnings Report
Date, such Company Periodic Report Date or such Request Date, as the case may be, in form and substance reasonably satisfactory to the
Agents, or, in </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">the case of clause (A)&nbsp;above, such Agents, as the case may be, to the effect that the statements contained in the
officers&rsquo; certificate referred to in Section&nbsp;5(f)&nbsp;hereof that was last furnished to the Agents or, in the case of clause
(A)&nbsp;above, such Agents, as the case may be, are true and correct as of the date of such certificate as though made at and as of the
date of such certificate (except that such statements shall be deemed to relate to the Registration Statement, the General Disclosure
Package and the Prospectus as amended and supplemented at the date of such certificate) or, in lieu of such certificate, a certificate
of the same tenor as the certificate referred to in Section&nbsp;5(f)&nbsp;hereof that, but modified as necessary to relate to the Registration
Statement, the General Disclosure Package and the Prospectus as amended and supplemented at the date of such certificate. As used in this
Section&nbsp;3(o), to the extent there shall be a sale of Shares on or following any Registration Statement Amendment Date, Company Earnings
Report Date, Company Periodic Report Date or Request Date, &ldquo;promptly&rdquo; shall be deemed to be at or prior to the Applicable
Time for such sale.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Delivery
of Future Opinions and Letters of Counsel. </I>Upon commencement of the offering of Shares under this Agreement, (A)&nbsp;each time Shares
are delivered to the applicable Agents as principal on a Settlement Date and (B)&nbsp;promptly after each Registration Statement Amendment
Date, Company Earnings Report Date, Company Periodic Report Date or Request Date, the Company will furnish or cause to be furnished to
the Agents or, in the case of clause (A)&nbsp;above, the applicable Agents the written opinions and letters of each of counsel to the
Company (who shall be reasonably acceptable to the Agents) or, in the case of clause (A)&nbsp;above, such Agents, as the case may be,)
and counsel to the Agents, dated such Settlement Date, such Registration Statement Amendment Date, such Company Earnings Report Date,
such Company Periodic Report Date or such Request Date, as the case may be, in form and substance reasonably satisfactory to the Agents,
or, in the case of clause (A)&nbsp;above, such Agents, as the case may be, of the same tenor as the respective opinions and letters referred
to in Section&nbsp;5(b)&nbsp;and 5(c), as applicable, hereof but modified as necessary to relate to the Registration Statement, the General
Disclosure Package and the Prospectus as amended and supplemented to the date of such opinion and letter or, in lieu of any such opinion
and letter, counsel last furnishing such opinion and letter to the Agents or, in the case of clause (A)&nbsp;above, such Agents, as the
case may be, shall furnish the Agents or, in the case of clause (A)&nbsp;above, such Agents, as the case may be, with a letter substantially
to the effect that the Agents or, in the case of clause (A)&nbsp;above, such Agents, as the case may be, may rely on such counsel&rsquo;s
last opinion and letter to the same extent as though each were dated the date of such letter authorizing reliance (except that statements
in such last opinion and letter shall be deemed to relate to the Registration Statement, the General Disclosure Package and the Prospectus
as amended and supplemented to the date of such letter authorizing reliance). As used in this Section&nbsp;3(p), to the extent there shall
be a sale of Shares on or following any Registration Statement Amendment Date, Company Earnings Report Date, Company Periodic Report Date
or Request Date, &ldquo;promptly&rdquo; shall be deemed to be at or prior to the Applicable Time for such sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Delivery
of Future Accountants&rsquo; Letters</I>. Upon commencement of the offering of Shares under this Agreement, (A)&nbsp;each time Shares
are delivered to the applicable Agents as principal on a Settlement Date and (B)&nbsp;promptly after each Registration Statement Amendment
Date, Company Earnings Report Date, Company Periodic Report Date or Request Date, the Company will cause its independent accountants to
furnish to the Agents or, in the case of clause (A)&nbsp;above, the applicable Agents a letter, dated such Settlement Date, such Registration
Statement Amendment Date, such Company Earnings Report Date, such Company Periodic Report Date or such Request Date, as the case may be,
in form and substance reasonably satisfactory to the Agents, or, in the case of clause (A)&nbsp;above, such Agents, as the case may be,
of the same tenor as the letter referred to in Section&nbsp;5(d)&nbsp;hereof but modified as necessary to relate to the Registration Statement,
the General Disclosure Package and the Prospectus as amended and supplemented to the date of such letter. As used in this paragraph, to
the extent there shall be a sale of Shares on or following any Registration Statement Amendment Date, Company Earnings Report Date, Company
Periodic Report Date or Request Date, &ldquo;promptly&rdquo; shall be deemed to be at or prior to the Applicable Time for such sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Waiver
of Future Delivery Obligations</I>. The Company may notify the Agents by telephone (confirmed promptly by electronic mail), or by such
other method as the Company and the Agents shall mutually agree in writing, at any time until 5:00 p.m., New York City time, on the second
business day preceding any Representation Date (other than the Company Periodic Report Date relating to the date of filing of the Company&rsquo;s
Annual Report on Form&nbsp;10-K) that it does not intend to sell Shares under this Agreement for the period commencing on such Representation
Date and continuing until the next succeeding Representation Date. If the Company shall have provided such notice, the requirements to
provide the certificate pursuant to Section&nbsp;3(o)&nbsp;hereunder, legal </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">opinions and negative assurance letters, as the case may be,
pursuant to Section&nbsp;3(p)&nbsp;hereunder, a letter or letters from accountants pursuant to Section&nbsp;3(q)&nbsp;hereunder shall
be waived in respect of such Representation Date. Notwithstanding the foregoing, if the Company delivers an Issuance Notice to an Agent
at a time that is (i)&nbsp;following a Representation Date in respect of which deliveries to the Agents of the documents required by any
of Section&nbsp;3(o), Section&nbsp;3(p), and Section&nbsp;3(q)&nbsp;hereunder were waived, and (ii)&nbsp;prior to the next Representation
Date, such Agent shall not be obligated to sell any Shares pursuant to such Issuance Notice until all documents required by each such
applicable section of this Agreement shall have been provided to such Agent and the Company shall have provided such Agent with a customary
due diligence update.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Trading
in the Common Stock</I>. The Company consents to the Agents trading in the Company&rsquo;s Common Stock for their own account and for
the account of their clients at the same time as sales of Shares occur pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Non-Consummation
Offer</I>. If, to the knowledge of the Company, any filing required by Rule&nbsp;424 in connection with an offering of Shares shall not
have been made or the representations and warranties of the Company contained in this Agreement shall not be true and correct on the applicable
Settlement Date, the Company will offer to any person who has agreed to purchase Shares from or through an Agent the right to refuse to
purchase and pay for such Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(u)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Due
Diligence Review</I>. The Company will cooperate with any due diligence review reasonably requested by the Agents or counsel for the Agents,
fully and in a timely manner, in connection with offers and sales of Shares from time to time, including, without limitation, and upon
reasonable notice, providing information and making available documents and appropriate corporate officers, during regular business hours
and at the Company&rsquo;s principal offices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Renewal
Deadline</I>. If, immediately prior to the third anniversary of the initial effective date of the Registration Statement (the &ldquo;<U>Renewal
Deadline</U>&rdquo;), this Agreement is still in effect or any Shares purchased by an Agent as principal remain unsold, the Company will,
prior to the Renewal Deadline, (i)&nbsp;promptly notify the Agents and (ii)&nbsp;promptly file, if it is eligible to do so, an automatic
shelf registration statement relating to the Shares, in a form and substance satisfactory to the Agents. If, at the time the Company intends
to file such a new automatic shelf registration statement, it is not eligible to do so, the Company will, prior to the Renewal Deadline,
(i)&nbsp;promptly notify the Agents, (ii)&nbsp;promptly file a new shelf registration statement on the proper form relating to the Shares,
in a form and substance satisfactory to the Agents, (iii)&nbsp;use its reasonable best efforts to cause such new shelf registration statement
to be declared effective within 60 days after the Renewal Deadline and (iv)&nbsp;promptly notify the Agents of such effectiveness. The
Company will take all other action necessary or appropriate to permit the offering and sale of the Shares to continue as contemplated
in the expired Registration Statement. References herein to the &ldquo;Registration Statement&rdquo; shall include such new automatic
shelf registration statement or such new shelf registration statement, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(w)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Ceasing
Eligibility For Use of Shelf Registration Statement Form</I>. If, at any time, during the term of this Agreement or otherwise when Shares
purchased by an Agent as principal remain unsold, the Company receives a notice from the Commission pursuant to Rule&nbsp;401(g)(1)&nbsp;or
otherwise ceases to be eligible to use the shelf registration statement form, the Company will (i)&nbsp;promptly notify the Agents, (ii)&nbsp;promptly
file a new registration statement or post-effective amendment on the proper form relating to such Shares, in form and substance satisfactory
to the Agents, (iii)&nbsp;use its best efforts to cause such new registration statement or post-effective amendment to be declared effective
as soon as practicable and (iv)&nbsp;promptly notify the Agents of such effectiveness. The Company will take all other action necessary
or appropriate to permit the offering and sale of the Shares to continue as contemplated in the Registration Statement that was the subject
of the Rule&nbsp;401(g)(1)&nbsp;notice or for which the Company has otherwise become ineligible. References herein to the &ldquo;Registration
Statement&rdquo; shall include such new registration statement or post-effective amendment, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Regulation
M Exemption</I>. If the exemptive provisions set forth in Rule&nbsp;101(c)(1)&nbsp;of Regulation M under the 1934 Act become satisfied
with respect to the Company or the Shares, the Company shall promptly notify the Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;4.
</FONT><U>Payment of Expenses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Expenses</I>.
The Company will pay or cause to be paid all expenses incident to the performance of their obligations under this Agreement, including
(i)&nbsp;the preparation, printing and filing of the Registration Statement (including financial statements and exhibits) as originally
filed and each amendment thereto, (ii)&nbsp;the preparation, printing and delivery to the Agents of copies of any preliminary prospectus,
any Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements thereto and any costs associated with electronic
delivery of any of the foregoing by the Agents to investors, (iii)&nbsp;the preparation, issuance and delivery of the certificates for
the Shares, including any stock or other transfer taxes and any stamp or other duties payable upon the sale, issuance or delivery of the
Shares to the Agents, (iv)&nbsp;the fees and disbursements of the Company&rsquo;s counsel, accountants and other advisors, (v)&nbsp;the
qualification of the Shares under securities laws in accordance with the provisions of Section&nbsp;3(g)&nbsp;hereof, including filing
fees and the reasonable fees and disbursements of counsel for the Agents in connection therewith and in connection with the preparation
of the Blue Sky Survey and any supplement thereto, (vi)&nbsp;the fees and expenses of any transfer agent or registrar for the Shares,
(vii)&nbsp;the costs and expenses of the Company relating to investor presentations on any &ldquo;road show&rdquo; undertaken in connection
with the marketing of the Shares, (viii)&nbsp;the filing fees incident to, and the reasonable fees and disbursements of counsel for the
Agents in connection with, the review by FINRA of the terms of sales of Shares, which amount shall not exceed $25,000 in the aggregate,
(ix)&nbsp;the fees and expenses incurred in connection with the listing of the Shares on the NYSE, (x)&nbsp;the reasonable documented
out-of-pocket expenses of the Agents, including the reasonable fees, disbursements and expenses of counsel for the Agents in connection
with this Agreement and the Registration Statement and ongoing services in connection with the transactions contemplated hereunder, which
amount shall not exceed $150,000 in the aggregate and (xi)&nbsp;the costs and expenses (including, without limitation, any damages or
other amounts payable in connection with legal or contractual liability) associated with the reforming of any contracts for the sale of
Shares caused by a breach of the representation contained in the second sentence of Section&nbsp;1(a)(ii)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;5.
</FONT><U>Conditions of Agents&rsquo; Obligations</U>. The obligations of the Agents hereunder are subject to the accuracy of the representations
and warranties of the Company contained herein or in certificates of any officer of the Company delivered pursuant to the provisions hereof
at each Representation Date, to the performance by the Company of its covenants and other obligations hereunder, and to the following
further conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Effectiveness
of Registration Statement and Filing of Prospectus</I>. The Company shall have filed the Registration Statement with the Commission not
earlier than three years prior to the date hereof and the Registration Statement was declared effective by the Commission on February&nbsp;11,
2021. The Company shall have filed with the Commission the Prospectus on or prior to the date of this Agreement and any subsequent Base
Prospectus or Prospectus Supplement prior to any Applicable Time and related Settlement Date, as applicable, in each case in the manner
and within the time period required by Rule&nbsp;424(b), and each Issuer Free Writing Prospectus, if any, in the manner and within the
time period required by Rule&nbsp;433. No stop order suspending the effectiveness of the Registration Statement or any post-effective
amendment thereto has been issued under the 1933 Act, no notice of objection of the Commission to the use of the Registration Statement
or any post-effective amendment thereto pursuant to Rule&nbsp;401(g)(1)&nbsp;has been received by the Company, no order preventing or
suspending the use of any preliminary prospectus or the Prospectus or any amendment or supplement thereto has been issued and no proceedings
for any of those purposes have been instituted or are pending or, to the Company&rsquo;s knowledge, contemplated. The Company shall have
complied with any and all requests for additional information on the part of the Commission to the reasonable satisfaction of the Agents.
The Company shall have paid the required Commission filing fees relating to the Shares as specified in Section&nbsp;3(a)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Opinion
of Counsel for the Agents</I>. On the date of this Agreement, the Agents shall have received the favorable written opinion or opinions
of Shearman&nbsp;&amp; Sterling LLP, counsel for the Agents, dated such date, with respect to such matters as the Agents may reasonably
request. In giving such opinion or opinions, such counsel may rely, as to all matters governed by the laws of jurisdictions other than
the laws of the State of New York, the General Corporation Law of the State of Delaware and the federal securities laws of the United
States, upon the opinions of counsel satisfactory to the Agents. Such counsel may also state that, insofar as such opinion involves factual
matters, they have relied, to the extent they deem proper, upon certificates of officers and other representatives of the Company and
certificates of public officials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Opinions
of Counsel to the Company</I>. On the date of this Agreement, the Agents shall have received:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
favorable written opinion or opinions of Duane Morris LLP, counsel to the Company, dated such date, to the effect as the Agents may reasonably
request; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
favorable written opinion or opinions of Davidson, Davidson&nbsp;&amp; Kappel, LLC, intellectual property counsel to the Company, dated
such date, to the effect as the Agents may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Accountants&rsquo;
Letter</I>. On the date of this Agreement, the Agents shall have received a letter from WithumSmith+Brown, PC, dated such date, in form
and substance satisfactory to the Agents, containing statements and information of the type ordinarily included in accountants&rsquo;
 &ldquo;comfort letters&rdquo; to underwriters with respect to the financial statements and other financial information included in the
Registration Statement, the General Disclosure Package and the Prospectus or any amendment or supplement thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Officer&rsquo;s
Certificate on Size of ATM Program</I>. On the date of this Agreement, the Company shall have furnished to the Agents a certificate of
an executive officer of the Company, dated such date, in a form satisfactory to the Agents, stating the minimum gross sales price per
share for sales of Shares pursuant to this Agreement and the maximum number of Shares that may be issued and sold pursuant to this Agreement
or, alternatively, the maximum gross proceeds from such sales, as duly authorized by the Company&rsquo;s board of directors or a duly
authorized committee thereof, and specify the number of Shares that have been approved for listing subject to official notice of issuance,
on the NYSE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Officers&rsquo;
Certificate for the Company</I>. On the date of this Agreement, there shall not have been, since the date of the latest audited financial
statements included in the Registration Statement, the General Disclosure Package and the Prospectus or since the respective dates as
of which information is given in the Registration Statement, the General Disclosure Package and the Prospectus, any Material Adverse Change,
and the Agents shall have received a certificate of the Chief Executive Officer or President of the Company and of the Chief Financial
Officer or Chief Accounting Officer of the Company, dated such date, to the effect that (A)&nbsp;there has been no such Material Adverse
Change, (B)&nbsp;the representations and warranties of the Company in this Agreement are true and correct with the same force and effect
as though expressly made on and as of such date, (C)&nbsp;the Company has complied with all agreements and satisfied all conditions on
its part to be performed or satisfied on or prior to such date and (D)&nbsp;no stop order suspending the effectiveness of the Registration
Statement or any post-effective amendment thereto has been issued under the 1933 Act, no notice of objection of the Commission to the
use of the Registration Statement or any post-effective amendment thereto pursuant to Rule&nbsp;401(g)(1)&nbsp;has been received by the
Company, no order preventing or suspending the use of any preliminary prospectus or the Prospectus or any amendment or supplement thereto
has been issued and no proceedings for any of those purposes have been instituted or are pending or, to their knowledge, contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Chief
Financial Officer&rsquo;s Certificate</I>. On the date of this Agreement, the Agents shall have received from the chief financial officer
of the Company a certificate with respect to certain financial information contained in the Registration Statement, the General Disclosure
Package and the Prospectus, which certificate shall be in form and substance reasonably acceptable to the Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Listing</I>.
The Shares shall have been approved for listing, subject to official notice of issuance, on the NYSE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Additional
Documents</I>. On the date of this Agreement, counsel for the Agents shall have been furnished with such documents and opinions as they
may reasonably require for the purpose of enabling them to render the opinions or make the statements requested by the Agents, or in order
to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the covenants, obligations or conditions,
contained herein; and all proceedings taken by the Company in connection with the issuance and sale of the Shares as contemplated herein
shall be satisfactory in form and substance to the Agents and counsel for the Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Termination
of this Agreement</I>. If any condition specified in this Section&nbsp;shall not have been fulfilled when and as required to be fulfilled,
this Agreement may be terminated by the applicable Agents by notice to the Company at any time, and any such termination shall be without
liability of any party to any other party </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">except the provisions of Sections 1, 3(h), 4, 6, 7, 8, 10, 12, 13, 14, 15 and 16 hereof shall
remain in full force and effect notwithstanding such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;6.
</FONT><U>Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Indemnification
of the Agents</I>. The Company agrees to indemnify and hold harmless the Agents, their respective affiliates (as such term is defined
in Rule&nbsp;501(b)&nbsp;of the 1933 Act Regulations (each, an &ldquo;<U>Affiliate</U>&rdquo;)), selling agents, officers and directors
and each person, if any, who controls an Agent within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or alleged untrue
statement of a material fact contained in the Registration Statement (or any amendment thereto), including any information deemed to be
a part thereof pursuant to Rule&nbsp;430B, or the omission or alleged omission therefrom of a material fact required to be stated therein
or necessary to make the statements therein not misleading or arising out of any untrue statement or alleged untrue statement of a material
fact included (A)&nbsp;in any preliminary prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package or the Prospectus
(or any amendment or supplement thereto) or (B)&nbsp;in any materials or information provided to investors by, or with the approval of,
the Company in connection with the marketing of any offering of Shares (&ldquo;<U>Marketing Materials</U>&rdquo;), including any roadshow
or investor presentations made to investors by the Company (whether in person or electronically), or the omission or alleged omission
in any preliminary prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package or the Prospectus (or any amendment
or supplement thereto) or in any Marketing Materials of a material fact necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement
of any litigation, or any investigation or proceeding by any Governmental Entity, commenced or threatened, or of any claim whatsoever
based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided that (subject to Section&nbsp;6(d)&nbsp;below)
any such settlement is effected with the written consent of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>against
any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by the Agents), reasonably incurred
in investigating, preparing or defending against any litigation, or any investigation or proceeding by any Governmental Entity, commenced
or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission,
to the extent that any such expense is not paid under (i)&nbsp;or (ii)&nbsp;above;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">provided, however, that this indemnity agreement shall not apply to
any loss, liability, claim, damage or expense to the extent arising out of any untrue statement or omission or alleged untrue statement
or omission made in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant
to Rule&nbsp;430B, or in the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance upon and
in conformity with information furnished to the Company by the Agents in writing expressly for use therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Indemnification
of Company, Directors and Officers</I>. Each Agent, severally and not jointly, agrees to indemnify and hold harmless the Company, its
directors, each of its officers who signed the Registration Statement, and each person, if any, who controls the Company within the meaning
of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act against any and all loss, liability, claim, damage and expense described
in the indemnity contained in Section&nbsp;6(a)&nbsp;hereof, as incurred, but only with respect to untrue statements or omissions, or
alleged untrue statements or omissions, made in the Registration Statement (or any amendment thereto), including any information deemed
to be a part thereof pursuant to Rule&nbsp;430B, or in the General Disclosure Package or the Prospectus (or any amendment or supplement
thereto) in reliance upon and in conformity with the information furnished to the Company by such Agent in writing expressly for use therein,
it being understood and agreed upon that the only such information furnished by any Agent consists of each Agent&rsquo;s name as set forth
on the cover page&nbsp;of the Prospectus and under &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Actions
against Parties; Notification</I>. Each indemnified party shall give notice as promptly as reasonably practicable to each indemnifying
party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying
party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced as a result
thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement.
In the case of parties indemnified pursuant to Section&nbsp;6(a)&nbsp;hereof, counsel to the indemnified parties shall be selected by
the Agents, and, in the case of parties indemnified pursuant to Section&nbsp;6(b)&nbsp;hereof, counsel to the indemnified parties shall
be selected by the Company. An indemnifying party may participate at its own expense in the defense of any such action; provided, however,
that counsel to the indemnifying party shall not (except with the prior written consent of the indemnified party) also be counsel to the
indemnified party. In no event shall the indemnifying parties be liable for fees and expenses of more than one counsel (in addition to
any local counsel) separate from their own counsel for all indemnified parties in connection with any one action or separate but similar
or related actions in the same jurisdiction arising out of the same general allegations or circumstances. No indemnifying party shall,
without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect
to any litigation, or any investigation or proceeding by any Governmental Entity, commenced or threatened, or any claim whatsoever in
respect of which indemnification or contribution could be sought under this Section&nbsp;6 or Section&nbsp;7 hereof (whether or not the
indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i)&nbsp;includes an unconditional
release of each indemnified party from all liability arising out of such litigation, investigation, proceeding or claim and (ii)&nbsp;does
not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Settlement
without Consent if Failure to Reimburse</I>. If at any time an indemnified party shall have requested an indemnifying party to reimburse
the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the
nature contemplated by Section&nbsp;6(a)(ii)&nbsp;hereof effected without its written consent if (i)&nbsp;such settlement is entered into
more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii)&nbsp;such indemnifying party shall have received
notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii)&nbsp;such indemnifying party
shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;7.
</FONT><U>Contribution</U>. If the indemnification provided for in Section&nbsp;6 hereof is for any reason unavailable to or insufficient
to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each
indemnifying party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such
indemnified party, as incurred, (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company,
on the one hand, and the applicable Agents, on the other hand, from the applicable offering of Shares or (ii)&nbsp;if the allocation provided
by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to in clause (i)&nbsp;above but also the relative fault of the Company, on the one hand, and the applicable Agents, on the other
hand, in connection with the statements or omissions which resulted in such losses, liabilities, claims, damages or expenses, as well
as any other relevant equitable considerations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The relative benefits received by the Company,
on the one hand, and the applicable Agents, on the other hand, in connection with the applicable offering of Shares shall be deemed to
be in the same proportion as the total net proceeds from such offering (before deducting expenses) received by the Company, on the one
hand, bear to the total commissions or underwriting discounts received by the applicable Agents, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The relative fault of the Company, on the one hand,
and the applicable Agents, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged
untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company
or by the applicable Agents and the parties&rsquo; relative intent, knowledge, access to information and opportunity to correct or prevent
such statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company and the Agents agree that it would
not be just and equitable if contribution pursuant to this Section&nbsp;7 were determined by pro rata allocation (even if the applicable
Agents were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable
considerations referred to above in this Section&nbsp;7. The aggregate amount of losses, liabilities, claims, damages and expenses incurred
by an indemnified party and referred to above in this Section&nbsp;7 shall be deemed to include any legal or other expenses </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">reasonably
incurred by such indemnified party in investigating, preparing or defending against any litigation, or any investigation or proceeding
by any Governmental Entity, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or
omission or alleged omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding the provisions of this Section&nbsp;7,
no Agent shall be required to contribute any amount in excess of the total commissions or underwriting discounts received by such Agent
in connection with Shares placed or underwritten by it for sale to the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No person guilty of fraudulent misrepresentation
(within the meaning of Section&nbsp;11(f)&nbsp;of the 1933 Act) shall be entitled to contribution from any person who was not guilty of
such fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For purposes of this Section&nbsp;7, each person,
if any, who controls an Agent within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act and an Agent&rsquo;s
Affiliates, selling agents, officers and directors shall have the same rights to contribution as such Agent, and each director of the
Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the
meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act shall have the same rights to contribution as the Company.
The Agents&rsquo; respective obligations to contribute pursuant to this Section&nbsp;7 are several in proportion to the number of Shares
placed or underwritten by it in the applicable offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;8.
</FONT><U>Representations, Warranties and Agreements to Survive</U>. All representations, warranties and agreements contained in this
Agreement or in certificates of officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect
regardless of (i)&nbsp;any investigation made by or on behalf of an Agent or its Affiliates, selling agents, officers or directors or
any person controlling such Agent, or the Company or its officers or directors, or any person controlling the Company and (ii)&nbsp;delivery
of and payment for the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;9.
</FONT><U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This
Agreement may be terminated for any reason, at any time, by either the Company or an Agent, as to itself, upon the giving of five days
prior written notice to the other parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
applicable Agents may terminate a Terms Agreement to which they are a party, at any time at or prior to the Settlement Date, (i)&nbsp;if
there has been, in such judgment of such Agents, since the time of execution of such Terms Agreement or since the respective dates as
of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any Material Adverse Change,
or (ii)&nbsp;if there has occurred any material adverse change in the financial markets in the United States or the international financial
markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or development involving a prospective
change in national or international political, financial or economic conditions, in each case the effect of which is such as to make it,
in the judgment of such Agents, impracticable or inadvisable to proceed with the completion of the offering of Shares contemplated by
such Terms Agreement or to enforce contracts for the sale of such Shares, or (iii)&nbsp;if trading in any securities of the Company has
been suspended or materially limited by the Commission or the NYSE, or (iv)&nbsp;if trading generally on the NYSE, the NYSE Amex or Nasdaq
has been suspended or materially limited, or minimum or maximum prices for trading have been fixed, or maximum ranges for prices have
been required, by any of said exchanges or by order of the Commission, FINRA or any other Governmental Entity, or (v)&nbsp;if a material
disruption has occurred in commercial banking or securities settlement or clearance services in the United States, or (vi)&nbsp;if a banking
moratorium has been declared by either Federal or New York authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
the Company and two or more Agents enter into a Terms Agreement pursuant to which such Agents agree to purchase Shares from the Company
as principal and one or more of such Agents shall fail at the Settlement Date to purchase the Shares which it or they are obligated to
purchase (the &ldquo;Defaulted Shares&rdquo;), then the nondefaulting Agents shall have the right, within 24 hours thereafter, to make
arrangements for one of them or one or more other Agents or underwriters to purchase all, but not less than all, of the Defaulted Shares
in such amounts as may be agreed upon and upon the terms herein set forth; provided, however, that if such arrangements shall not have
been completed within such 24-hour period, then:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>if
the number of Defaulted Shares does not exceed 10% of the number of Shares to be so purchased by all of such Agents on the Settlement
Date, the nondefaulting Agents shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions that
their respective initial purchase obligation bears to the purchase obligations of all nondefaulting Agents; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>if
the number of Defaulted Shares exceeds 10% of the number of Shares to be so purchased by all of such Agents on the Settlement Date, such
Terms Agreement shall terminate without liability on the part of any nondefaulting Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No action taken pursuant to this Section&nbsp;9(c)&nbsp;shall relieve
any defaulting Agent from liability in respect of its default. In the event of any such default which does not result in a termination
of such Terms Agreement, either the nondefaulting Agents or the Company shall have the right to postpone the Settlement Date for a period
not exceeding seven days in order to effect any required changes in the Registration Statement, the General Disclosure Package or the
Prospectus or in any other documents or arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
the event of any termination under this Section&nbsp;9, neither party will have any liability to the other party hereto, except that (i)&nbsp;the
Agents shall be entitled to any commissions earned in accordance with Section&nbsp;2(b)&nbsp;hereof, (ii)&nbsp;if at the time of termination
(a)&nbsp;an Agent shall own any Shares purchased by it as principal or (b)&nbsp;an offer to purchase any Shares has been accepted by the
Company but the Settlement Date has not occurred, the covenants set forth in Section&nbsp;3 hereof shall remain in effect until such Shares
are resold or so delivered, as the case may be, and (iii)&nbsp;the covenant set forth in Section&nbsp;3(h)&nbsp;hereof, the provisions
of Section&nbsp;4 hereof, the indemnity and contribution agreements set forth in Sections 6 and 7 hereof, and the provisions of Sections
8, 10, 12, 13, 14, 15 and 16 hereof shall remain in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;10.
</FONT><U>Notices</U>. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given
if mailed or transmitted by any standard form of telecommunication. Notices to the Agents shall be directed to BofA at One Bryant Park,
New York, New York 10036, Attention: Syndicate Department (facsimile: (646) 855-3073), with a copy to ECM Legal (facsimile: (212) 230-8730);
ThinkEquity at 17 State Street, 41st Floor, New York, New York 10004, Attention: Head of Investment Banking (e-mail: notices@think-equity.com);
and with a copy to Shearman&nbsp;&amp; Sterling LLP at 599 Lexington Avenue, New York, New York 10022, Attention: Ilir Mujalovic; and
notices to the Company shall be directed to it at 1055 Westlakes Drive, Suite&nbsp;300, Berwyn, Pennsylvania 19312, Attention: Maria Maccecchini,
Ph.D. (facsimile: (610) 727-4001, e-mail: maccecchini@annovisbio.com); with a copy to Duane Morris LLP at 30 S. 17th Street, Philadelphia,
Pennsylvania 19103, Attention: Kathleen M. Shay,&nbsp;Esq. and Darrick M. Mix,&nbsp;Esq..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;11.
</FONT><U>No Advisory or Fiduciary Relationship</U>. The Company acknowledges and agrees that (a)&nbsp;each purchase and sale of Shares
pursuant to this Agreement, including the determination of the respective initial public offering prices of Shares, if any, and any related
discounts and commissions, is an arm&rsquo;s-length commercial transaction between the Company, on the one hand, and the applicable Agents,
on the other hand, and does not constitute a recommendation, investment advice, or solicitation of any action by the Agents, (b)&nbsp;the
Agents have not assumed and will not assume any advisory or fiduciary responsibility in favor of the Company or other affiliates with
respect to any offering of Shares or the process leading thereto (irrespective of whether the applicable Agents have advised or are currently
advising the Company or other affiliates on other matters) or any other obligation to the Company except the obligations expressly set
forth in this Agreement, (c)&nbsp;the Agents and their respective affiliates may be engaged in a broad range of transactions that involve
interests that differ from those of the Company, (d)&nbsp;the Agents have not provided any legal, accounting, financial, regulatory, investment
or tax advice to the Company or any other person or entity with respect to any offering of Shares and the Company has consulted its own
respective legal, accounting, financial, regulatory and tax advisors to the extent it deemed appropriate, and (e)&nbsp;none of the activities
of the Agents in connection with the transactions contemplated herein constitutes a recommendation, investment advice or solicitation
of any action by the Agents with respect to any entity or natural person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;12.
</FONT><U>Recognition of the U.S. Special Resolution Regimes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
the event that any Agent that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer
from such Agent of this Agreement, and any interest and obligation in or </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">under this Agreement, will be effective to the same extent as
the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were
governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
the event that any Agent that is a Covered Entity or a BHC Act Affiliate of such Agent becomes subject to a proceeding under a U.S. Special
Resolution Regime, Default Rights under this Agreement that may be exercised against such Agent are permitted to be exercised to no greater
extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws
of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Section&nbsp;12, a &ldquo;</FONT>BHC Act Affiliate&rdquo; has the meaning assigned to the term &ldquo;affiliate&rdquo;
in, and shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k). &ldquo;Covered Entity&rdquo; means any of the following: (i)&nbsp;a
 &ldquo;covered entity&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b); (ii)&nbsp;a &ldquo;covered
bank&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or (iii)&nbsp;a &ldquo;covered FSI&rdquo;
as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b). <B>&ldquo;</B>Default Right&rdquo; has the
meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable.
 &ldquo;U.S. Special Resolution Regime&rdquo; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated
thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;13.</FONT><U>Parties</U>.
This Agreement shall each inure to the benefit of and be binding upon the Agents and the Company and their respective successors. Nothing
expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation, other than the Agents,
their respective Affiliates and selling agents, the Company and their respective successors and the controlling persons and officers and
directors referred to in Sections 6 and 7 and their heirs and legal representatives, any legal or equitable right, remedy or claim under
or in respect of this Agreement or any provision herein contained. This Agreement and all conditions and provisions hereof are intended
to be for the sole and exclusive benefit of the Agents, their respective Affiliates and selling agents, the Company and their respective
successors, and said controlling persons and officers and directors and their heirs and legal representatives, and for the benefit of
no other person, firm or corporation. No purchaser of Shares shall be deemed to be a successor by reason merely of such purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;14.
</FONT><U>Trial by Jury</U>. Each of the Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders
and affiliates), and the Agents hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial
by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;15.
</FONT><U>GOVERNING LAW</U>. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE
GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;16.
</FONT><U>Consent to Jurisdiction; Waiver of Immunity</U>. Each of the Company and the Agent agrees that any legal suit, action or proceeding
arising out of or based upon this Agreement or the transactions contemplated hereby (&ldquo;<U>Related Proceedings</U>&rdquo;) shall be
instituted in (i)&nbsp;the federal courts of the United States of America located in the City and County of New York, Borough of Manhattan
or (ii)&nbsp;the courts of the State of New York located in the City and County of New York, Borough of Manhattan (collectively, the &ldquo;<U>Specified
Courts</U>&rdquo;), and irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement
of a judgment of any Specified Court (a &ldquo;<U>Related Judgment</U>&rdquo;), as to which such jurisdiction is non-exclusive) of the
Specified Courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to a party&rsquo;s
address set forth in Section&nbsp;10 hereof shall be effective service of process upon such party for any suit, action or proceeding brought
in any Specified Court. Each of the Company and the Agents irrevocably and unconditionally waives any objection to the laying of venue
of any suit, action or proceeding in the Specified Courts and irrevocably and unconditionally waives and agrees not to plead or claim
in any Specified Court that any such suit, action or proceeding brought in any Specified Court has been brought in an inconvenient forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;17.
</FONT><U>TIME</U>. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER
TO NEW YORK CITY TIME.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;18.
</FONT><U>Counterparts and Electronic Signatures</U>. This Agreement may be executed in any number of counterparts, each of which shall
be deemed to be an original, but all such counterparts shall together constitute one and the same Agreement. Electronic signatures complying
with the New York Electronic Signatures and Records Act (N.Y. State Tech. &sect;&sect; 301-309), as amended from time to time, or other
applicable law will be deemed original signatures for purposes of this Agreement. Transmission by telecopy, electronic mail or other transmission
method of an executed counterpart of this Agreement will constitute due and sufficient delivery of such counterpart.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section&nbsp;19.
</FONT><U>Effect of Headings</U>. The Section&nbsp;headings herein are for convenience only and shall not affect the construction hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">If the foregoing is in accordance with your understanding
of our agreement, please sign and return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts,
will become a binding agreement between the Agents and the Company in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Annovis Bio,&nbsp;Inc.</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Maria Maccecchini</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">Name: Maria Maccecchini&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: President and Chief Executive Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted as of the date hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BofA Securities,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Gerardo Uhaghs Carrion</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%">Name: Gerardo Uhaghs Carrion&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title: Managing Director</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ThinkEquity LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Eric Lord</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%">Name: Eric Lord</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title: Head of Investment Banking</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page to Sales Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Annex I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ANNOVIS BIO,&nbsp;INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common Stock<BR>
($0.0001 par value)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TERMS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BofA Securities,&nbsp;Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ThinkEquity LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">c/o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">BofA Securities,&nbsp;Inc.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">One Bryant Park</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">New York, New York 10036</FONT></TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, New York, New York 10036Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">c/o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ThinkEquity LLC</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">17 State Street, 41st Floor</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">New York, New York 10004</FONT></TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annovis
Bio,&nbsp;Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), proposes, on the basis of the representations and warranties,
and subject to the terms and conditions, stated herein and in the ATM Equity Offering</FONT><B><SUP>SM </SUP></B>Sales Agreement, dated
March&nbsp;31, 2023 (the &ldquo;<U>Sales Agreement</U>&rdquo;), between the Company and the agents party thereto, to issue and sell to
BofA Securities,&nbsp;Inc. and ThinkEquity LLC as principal for resale (collectively, the &ldquo;Underwriters&rdquo;), and the Underwriters
severally agree to purchase from the Company the shares of Common Stock specified in the Schedule A hereto (the &ldquo;[<U>Initial] Securities</U>&rdquo;),
[and to grant to the Underwriters the option to purchase the additional shares of Common Stock specified in the Schedule A hereto (the
 &ldquo;<U>Option Securities</U>&rdquo;, and together with the Initial Securities the &ldquo;Securities&rdquo;), in each case]* on the
terms specified in Schedule A hereto. Capitalized terms but and not defined herein have the respective meanings ascribed thereto in the
Sales Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[The
Company grants an option to the Underwriters, severally and not jointly, to purchase up to an additional </FONT>[&#9679;] Option Securities
at the price per share set forth in Schedule A hereto, less an amount per share equal to any dividends or distributions declared by the
Company and payable on the Initial Securities but not payable on the Option Securities. The option hereby granted may be exercised for
30&nbsp;days after the date hereof and may be exercised in whole or in part at any time from time to time upon notice by the Underwriters
to the Company setting forth the number of Option Securities as to which the several Underwriters are then exercising the option and the
time and date of payment and delivery for such Option Securities. Any such time and date of delivery (a &ldquo;Date of Delivery&rdquo;)
shall be determined by the Underwriters, but shall not be later than seven full business days after the exercise of said option, nor in
any event prior to the Settlement Date (as defined below). If the option is exercised as to all or any portion of the Option Securities,
each of the Underwriters, acting severally and not jointly, will purchase that proportion of the total number of Option Securities then
being purchased which the number of Initial Securities set forth in Schedule A hereto opposite the name of such Underwriter bears to the
total number of Initial Securities, subject, in each case, to such adjustments as BofA in its sole discretion shall make to eliminate
any sales or purchases of fractional shares. For purposes of clarity, the parties hereto agree that the officers&rsquo; certificate, opinions
and letter of counsel and accountants&rsquo; letter referred to in Section&nbsp;3(o), (p)&nbsp;and (q), respectively, of the Sales Agreement
are required to be delivered by or on behalf of the Company on the Settlement Date.]*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Payment of the purchase price for, and delivery
of certificates for, the Initial Securities shall be made at the offices of Shearman&nbsp;&amp; Sterling LLP, or at such other place
as shall be agreed upon by the Underwriters and the Company, at 9:00&nbsp;A.M.&nbsp;(New</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> York City time) on the second (or third, if the
pricing occurs after 4:30 P.M.&nbsp;(New York City time) on any given day) business day after the date hereof (unless postponed in accordance
with the provisions of Section&nbsp;9(c)&nbsp;of the Sales Agreement), or such other time not later than ten business days after such
date as shall be agreed upon by the Underwriters and the Company (such time and date of payment and delivery being herein called &ldquo;<U>Settlement
Date</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, in the event that any or all of the
Option Securities are purchased by the Underwriters, payment of the purchase price for, and delivery of certificates for, such Option
Securities shall be made at the above-mentioned offices, or at such other place as shall be agreed upon by the Underwriters and the Company,
on each Date of Delivery as specified in the notice from the Underwriters to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Payment shall be made to the Company by wire transfer
of immediately available funds to a bank account designated by the Company against delivery to the Underwriters for their respective accounts
for the Securities to be purchased by them. It is understood that each Underwriter has authorized BofA as representative of the Underwriters,
for its account, to accept delivery of, receipt for, and make payment of the purchase price for, the Initial Securities and the Option
Securities, if any, which it has agreed to purchase. BofA, individually and not as representative of the Underwriters, may (but shall
not be obligated to) make paymsent of the purchase price for the Initial Securities or the Option Securities, if any, to be purchased
by any Underwriter whose funds have not been received by the Settlement Date or the relevant Date of Delivery, as the case may be, but
such payment shall not relieve such Underwriter from its obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each of the provisions of the Sales Agreement not
related solely to the Agent, as agent of the Company, is incorporated herein by reference in its entirety, and shall be deemed to be part
of this Terms Agreement to the same extent as if each such provision had been set forth in full herein. Each of the representations and
warranties set forth in the Sales Agreement shall be deemed to have been made at and as of the date of this Terms Agreement, the Applicable
Time and any Date of Delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the foregoing is in accordance with your understanding
of our agreement, please sign and return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts,
will become a binding agreement between the Underwriters and the Company in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">THIS TERMS AGREEMENT AND ANY CLAIM, CONTROVERSY
OR DISPUTE ARISING UNDER OR RELATED TO THIS TERMS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE
OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Annovis Bio,&nbsp;Inc.</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: &nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted as of the date hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BofA Securities,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: &nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ThinkEquity LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: &nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Include
only if the Underwriters have an option to purchase additional shares of Common Stock from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm2311180d2_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt; text-indent: -10pt; width: 30%">NEW YORK<BR>
LONDON<BR>
SINGAPORE<BR>
PHILADELPHIA<BR>
CHICAGO<BR>
WASHINGTON, DC<BR>
SAN FRANCISCO<BR>
SILICON VALLEY<BR>
SAN DIEGO<BR>
SHANGHAI<BR>
BOSTON<BR>
HOUSTON<BR>
LOS ANGELES<BR>
HANOI<BR>
HO CHI MINH CITY</TD>
    <TD STYLE="text-align: center; width: 40%"><P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2311180d2_ex5-1img03.jpg" ALT="">&nbsp;</P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0"><I>FIRM and AFFILIATE OFFICES</I></P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><I>www.duanemorris.com</I></P></TD>
  <TD STYLE="text-align: center; padding-left: 10pt; text-indent: -10pt; width: 30%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ATLANTA<BR>
BALTIMORE<BR>
WILMINGTON<BR>
MIAMI<BR>
BOCA RATON<BR>
PITTSBURGH<BR>
NEWARK<BR>
LAS VEGAS<BR>
CHERRY HILL<BR>
LAKE TAHOE<BR>
MYANMAR<BR>
OMAN<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>A GCC REPRESENTATIVE OFFICE OF DUANE
MORRIS</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>MEXICO CITY</U></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ALLIANCE WITH</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">MIRANDA &amp; ESTAVILLO</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SRI LANKA</U></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ALLIANCE WITH</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">GOWERS INTERNATIONAL<I>&nbsp;&nbsp;</I></P></TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2in 0pt 0">April 3, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2in 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.75pt; padding-bottom: 0.15in">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Annovis Bio, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1055 Westlakes Drive, Suite 300</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Berwyn, PA 1931</P></TD></TR>
  </TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:</B></FONT></TD><TD><B><U>Exhibit 5.1 to Prospectus Supplement</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are acting as counsel to
Annovis Bio, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), in connection with the issuance and sale (the &ldquo;Offering&rdquo;)
by the Company from time to time of common stock, $0.0001 par value per share (the &ldquo;Shares&rdquo;) pursuant to the ATM Equity Offering<SUP>SM</SUP>
Sales Agreement, March 31, 2023 (the &ldquo;<B>Agreement</B>&rdquo;), among the Company and BofA Securities, Inc. and ThinkEquity, as
sales agents. The Shares have been registered on a Registration Statement on Form S-3 (File no. 333-252625), (such registration statement,
including documents incorporated by reference therein and amendments thereto, the &ldquo;<B>Registration Statement</B>&rdquo;), filed
by the Company with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) on February 1, 2021 and declared effective
on February 11, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of rendering
this opinion, we have examined originals or copies (certified or otherwise identified to our satisfaction) of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Registration Statement, and the exhibits filed in connection therewith or incorporated by reference therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Company&rsquo;s base prospectus, dated February 11, 2021, relating to the offering of securities of the Company, which forms a part of,
and is substantially in the form included in, the Registration Statement (the &ldquo;<B>Base Prospectus</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Company&rsquo;s prospectus supplement, dated March 31, 2023, filed with the Commission pursuant to Rule 424(b) under the Securities Act
of 1933, as amended (the &ldquo;<B>Prospectus Supplement</B>&rdquo; and, together with the Base Prospectus, the &ldquo;<B>Prospectus</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="border-bottom: Black 1pt solid; vertical-align: top; text-align: left"><TD STYLE="font-variant: small-caps"><FONT STYLE="font-variant: small-caps">Duane Morris llp</FONT></TD><TD>&nbsp;</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">30 SOUTH 17TH STREET PHILADELPHIA, PA 19103-4196</TD><TD STYLE="text-align: right; width: 50%">PHONE: 215.979.1000 FAX: 215.979.1020</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><IMG SRC="tm2311180d2_ex5-1img02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">April 3, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Amended and Restated Certificate of Incorporation of the Company, as certified by an officer of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Amended and Restated Bylaws of the Company, as certified by an officer of the Company; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;resolutions
of the Board of Directors of the Company, as attested to by an officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also examined such
other certificates of public officials, such certificates of executive officers of the Company and such other records, agreements, documents
and instruments as we have deemed relevant and necessary as a basis for the opinions hereafter set forth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In such examination, we have
assumed (i) the genuineness of all signatures, (ii) the legal capacity of all natural persons, (iii) the authenticity of all documents
submitted to us as originals, (iv) the conformity to original documents of all documents submitted to us as certified, conformed or other
copies and the authenticity of the originals of such documents and (v) that all records and other information made available to us by
the Company on which we have relied are complete in all material respects. As to all questions of fact material to the opinion expressed
herein, we have relied solely upon the above-referenced certificates or comparable documents and upon the representations and warranties
contained in the Agreement and other documents delivered pursuant thereto, have not performed or had performed any independent research
of public records and have assumed that certificates of or other comparable documents from public officials dated prior to the date hereof
remain accurate as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the foregoing, we
are of the opinion that the Shares, when issued and delivered in accordance with the terms of the Agreement, the Registration Statement
and the Prospectus, will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing opinion is limited
to the laws of the State of Delaware, and we do not express any opinion herein concerning any other law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The opinion expressed herein
is rendered as of the date hereof and is based on existing law, which is subject to change. Where our opinion expressed herein refers
to events to occur at a future date, we have assumed that there will have been no changes in the relevant law or facts between the date
hereof and such future date. We do not undertake to advise you of any changes in the opinion expressed herein from matters that may hereafter
arise or be brought to our attention or to revise or supplement such opinions should the present laws of any jurisdiction be changed by
legislative action, judicial decision or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our opinion expressed herein
is limited to the matters expressly stated herein and no opinion is implied or may be inferred beyond the matters expressly stated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><IMG SRC="tm2311180d2_ex5-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">April 3, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Page 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to the use
of this letter as an exhibit to the Company&rsquo;s Current Report on Form 8-K filed with the Commission for incorporation by reference
into the Registration Statement and to any and all references to our firm in the Prospectus. In giving this consent, we do not admit that
we are &ldquo;experts&rdquo; within the meaning of Section 11 of the Securities Act or within the category of persons whose consent is
required under Section 7 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">Very truly yours,</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Duane Morris LLP</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>anvs-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaOAubOdzZR+CYkxtmBxbclanyYkHmMqeSXiQUBWAecL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:ANVS="http://annovisbio.com/20230331" elementFormDefault="qualified" targetNamespace="http://annovisbio.com/20230331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://annovisbio.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="anvs-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="anvs-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>anvs-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>anvs-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://annovisbio.com/role/Cover" xlink:href="anvs-20230331.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://annovisbio.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2311180d2_ex5-1img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2311180d2_ex5-1img03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  K -@# 2(  A$! Q$!_\0
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MJ_BU=/\ #>YM['X5Z1<W,J0P1V[.[NV%4;V[T =N.E%<[_PFVC"S-[YEQ]@
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MGDP6P<XQ]0*R_!/@C5=-LHM-UJW80QABL\%V1CG(&W\:]2P*7% '/#P;IO\
MSUO?_ EJ/^$-TW_GK>_^!#5T-% '/?\ "&Z;C_6WO_@0U'_"&Z;_ ,];W_P(
M:NAHH Y[_A#=-_YZWO\ X$M1_P (;IO_ #VO?_ EJZ&B@#GO^$-TW_GM>_\
=@2U:.FZ/;Z4CI;O,P<Y/FR%_YUH44 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2311180d2_ex5-1img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2311180d2_ex5-1img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  G +4# 2(  A$! Q$!_\0
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M2^UL"#;&?FA _P!>P]-BAL'U*^HKI]/GM-4T6WEA>.XM;B 8(.5=2*Y#P#X
M7PIJ&J7$Q:3_ $ATL-SY\N [3GV)( /^X/6@#!^,-O%:1>$;:",1PQ7@2-%Z
M*HV  ?A6YH^;GXS^(VO!NDM;.!;+>/N1LH+E?^!'D^]8'QPO;>WE\-"20;X[
MIIF0<D(-O.*[&]MM.U;4K37+9-5MKZ.+9'=VD/\ K(CSM8$%67OR/I0!G>,2
MUO\ $?P5-:<7<LL\,NWJ\.U2P/J!DFDL-/LV^,^KR-:PEETV&124'#EL%OKC
MC-:EI96D&M?VS=1ZQ?:@(S%'+<6^!"AZA%50!GUY/O4$&DP6_B.;75N?$)O9
MHUBDW6\>UD!R%QY?'U'/O0!2^*6FV,'P^ECAM((TCNH70)&%"EI1N(QT)R<_
M6NSCTG3HC&8["U0Q1F*/;$HVH<94<< X'%<_XEL;3Q38"QO!K<-MN#-';P!=
MQ!R"25)X/H16C'>NED;<MK#R'I<-:KO'Y)M_\=H Y;P-9V4GACQ=8SLMO8OJ
M]] Y!"".,@*<'H,"J,6H:WX$^QZ;XJMH+_PU#*D5MJ<2_/;[3^[,B^V!SC\3
M6W8>'["PT[5-/#:_-:ZF97N8Y85Y>089@0@(/XX]JFNM,@U*"VMM5DUO4+2!
MUD$$UJH61E^Z7*H"V.N. >^: .KM+J&^LH+RVD$D$\:RQN/XE89!_(T46J11
M6<$<$7DPK&JI'MV[% X&.V!VHH CO],L-5@6#4;&VO(5;>([B)9%#8(SA@><
M$\^]9W_"&^%O^A:T?_P!B_\ B:** +=AH.CZ5*TFG:38V<C#!:WMTC)'IE0*
MT*** "BBB@ HHHH **** "J&H:%I&K2+)J.E6-XZ#:K7%NDA ] 6!HHH DL-
M*T[2HFCTZPM;.-CEEMX5C!/J0H%6Z** ,BX\*^';N=Y[G0=+FF<EGDDLXV9B
M>I)(R:O66GV6F6_V>PL[>T@R6\N"(1KD]\ 8HHH LT444 %%%% !1110 444
$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2311180d2_ex5-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2311180d2_ex5-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  G +4# 2(  A$! Q$!_\0
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M2^UL"#;&?FA _P!>P]-BAL'U*^HKI]/GM-4T6WEA>.XM;B 8(.5=2*Y#P#X
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$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139901075505760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANNOVIS BIO, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001477845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2540421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1055 Westlakes Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Berwyn<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">727-3913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANVS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>tm2311180d2_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="anvs-20230331.xsd" xlink:type="simple"/>
    <context id="From2023-03-31to2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-03-31to2023-03-31">0001477845</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-03-31to2023-03-31">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-03-31to2023-03-31">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-03-31to2023-03-31">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-03-31to2023-03-31">ANNOVIS BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-03-31to2023-03-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-03-31to2023-03-31">001-39202</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-03-31to2023-03-31">26-2540421</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-03-31to2023-03-31">1055 Westlakes Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-03-31to2023-03-31">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-03-31to2023-03-31">Berwyn</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-03-31to2023-03-31">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-03-31to2023-03-31">19312</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-03-31to2023-03-31">610</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-03-31to2023-03-31">727-3913</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-03-31to2023-03-31">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-03-31to2023-03-31">ANVS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-03-31to2023-03-31">NYSE</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="From2023-03-31to2023-03-31">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-03-31to2023-03-31">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-03-31to2023-03-31">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-03-31to2023-03-31">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-03-31to2023-03-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2023-03-31to2023-03-31">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( ).+@U8'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ DXN#5I+1^G_O    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ DXN#5IE<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "3
MBX-6$*[*'8@$  #$$0  &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ DXN#5I^@&_"Q @  X@P   T
M         ( !S P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "3BX-6EXJ[
M',     3 @  "P              @ &H#P  7W)E;',O+G)E;'-02P$"% ,4
M    " "3BX-6JL0B%C,!   B @  #P              @ &1$   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ DXN#5B0>FZ*M    ^ $  !H
M     ( !\1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ DXN#5F60>9(9 0  SP,  !,              ( !UA(  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  (!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2311180d2_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2311180d2_8k.htm">tm2311180d2_8k.htm</File>
    <File>anvs-20230331.xsd</File>
    <File>anvs-20230331_lab.xml</File>
    <File>anvs-20230331_pre.xml</File>
    <File>tm2311180d2_ex1-1.htm</File>
    <File>tm2311180d2_ex5-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2311180d2_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2021q4": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2311180d2_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "anvs-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "anvs-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "anvs-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ANVS",
   "nsuri": "http://annovisbio.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2311180d2_8k.htm",
      "contextRef": "From2023-03-31to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://annovisbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2311180d2_8k.htm",
      "contextRef": "From2023-03-31to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://annovisbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001104659-23-041009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-23-041009-xbrl.zip
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M]OY=8E=@]!O6@,#*($#IM6<"(P/&42T"%2$HC_&/SCQ--T2\"2!+B">,0/,
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M T.:"PAE//()@@QA<AGP3#?A7X$9;,@)'=Z,T'FZJ?R=Z'S@# 9<B%].5K0
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M#IBY"3#/+*>C@=]W/+!1YI^<^U#[TV.&/K$S8&>8 B7S0T;//+:K@.2G_%C
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M:;!Y84TZ1DG-E%*,SI4)'J, P1=G5/CC5UA+(OU0[_,86P0O/IOQ)!W"^+D
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MRCS(M,KCKF6.;% #DAH$X41MNJC8QBR#LQUPSO"!9BD@S@#'-BD;"FL[<_\
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M<W520%RLEVNN5!(Z/02\3O$7CH1\<!"=7K%HI)!E2.K2STKNG<.G1/[9219
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MK"4U6?<D1 B&1 (P-Q]"MIA:>>\P0+3&:9^5O .^_7JP UC@7V\+&/ BOB,
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MW1U6FB8D-A[>Y$X7TPN/?;%V:F<-U<KK-&L@X\_P+50NB[Y>G-T0C'BX%?F
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MU06T78XB?E/5YR+_N=[96UZL)O%>=E1=CQ)&9TP+S!)C@+?HE&7$E6@>!VH
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MY!3?85ON#]=+GUU8?R7U- B]Q2VCCU!1!O*C"EV?<Z2U[09JR!1OC.D>(XC
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MP5I6*A)+VYN7K:A+.IG@)HE;P9'+'_5$2=J,(?*#N\M1L[9_NB>*!\:MB%)
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M+"')U7$?8A0"0DKR/30'3>9,VL_R+&/XJ3<"V 2&-V^$ZDW(^KQ(2B0$[V6
M%%*4=';QYVIO[.\!=A&N_)0.+Q24X4PPN$O/#L_>QM2Q PG4-JRR+L8167,=
M/A%9$%W/%R/-NJ[3F>L-JS?Z3Z,W[&TE]88.P]XQSF*PA*%2R,B'.JX9W,/N
MCR$&6D/+7C+J04#2WF7JS-J[SKO+'HY: &\N,RY!,-+#X%]"<2>J:7,NUPJ"
MQU36]Z #HJJG _6 $L[*5@^ (]067";#BS0FH^96L\E5PK2'EUD*)?Y:%1]I
M50R)Y;2B:L)F,-3]^4>[.>+W]!F;@G#HCZ95\P'B#0/Q38)D$GY##O+[*Z,D
MEI;&@LH'RG%N@5YJ BX%N0A-UA\APY0P<)4TC1_[034CQU=X?850-KTT8MR8
MQ+9\TOP-;[ <S"4V83J90T#OTT/3V#?<<H8?=D71TW!Q(</JN%*WKG)A#^4Z
M[0^] @4S+*K=VS7=FM^22Y>8]-,FJQ\AE[ZX<&LR?>KA?5,NW6 [M"73_15^
MO%PZ@);=EDR/'BJ7GI6MV?/Y96\N^XO'!F$ 1;VX8+1XY'D-D;C\'\)_-X (
M7;PAK)O*?H#I## 7CG-S^9XP? 9H#&%WMU%C^W#TK+JH70[.D [<2G71QD@W
MEWPK^9>/+/G[Y(Z(#CL'PW&R$Q-/Z\5$<R?FZ=,8$(4T!52+"[L:BF\J!=;2
MB>%+A0UWH$XB4\G!_+-XWQBA'D,M0R,XG976I^*+% :5PC?XPA\0?*8Q>6S4
MO03800: L8Y1"^9BS/7D:&$@;$H*Z,G:SY'%ZZ)YT#>: 9[#V,RQMC3ZH[R?
MY;GN&A:_-_7AL5M5+PN^8RB+<VO?/YBR.&EZ4->45XC>TLOB]"P&($Y\6!-Z
M+T:%2(D[4::P1O<"78+_TQ6>^<&W!_^/QX:;!I2;H>PRE,?; (%PPP5)H%NP
MV.3_"X0NM,C#^0< *?;E3,VDYLOE+R'+D^--<HBPYN':T]HD_SH?ZYO%0P]Q
M8*]LR3B Y]A5L&8)]U,M+IBV)^-'))"!XXIQ2B#0GV97<*>L@-F85\ \<P7,
M^KP"9G;.C"%V;>DDKZ*U.-I0MG<<;<;1FSAZ&T?O8O4F]<^Z^F=#_:,^6'N-
MZF;MC>Z^8780QL;+4#WFC7 8J#&'"\375?.+,MS/^,;I9^RH,0R&!DY@CLWR
MM#USWO*;B(6LH9>]%1BF9;@-^B6%T2\A):B,T4$.D5)IJ%-T3&0>DCXT7F#Z
M84F73".V909=;7TPG!&;U08?7Z^N&7)S'I\.E0H(,_4X:,5"G&0+(KVEWR;!
MHY5& ,H81/+0_H0LI3;91,I'8(<740C83B[@$L 6ZB*O++JFZ"(;I,E0$RHX
MO<^O(W\2RL!VOK*^*KZ"4&P8?*=.TUGN*?U>:PF3BP3"P 20H[VYO*C4 (W]
M&0.+:S:(N:5?0@$H84GJJDBOL7780CVH_RBS"H5D9)S-T1 3,PY$HWI=>H&Y
M OA,I [Q1]"E04DC</&FC11&2XU .H?.EWVH&QF'E"2D:CTX$<-79TOR8&-U
MV[C7A6E.M=,J1(]IF1('1W->GC^":]"CGX"SJY[G$-:&P@G\971_U#OS-.%
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MH$%I&Z?3HH(<?!HM"A1TP.(!7T+;HJJ+@@IAF0*785&8WP_% -\1'A";8#0
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M5;&.D*UOJIM6+1_=JE@4'>NK2*U'B=J'@@U]]-!UX?(@TO^IEP>/%;]3!I;
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M353&,/9@0/<$=LCT$HE116@Q/4B7QF2:J;=DM5E!@4WI$7\;$U5:X7@;(I%
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M2C\K!T30H6ZCDFUH#4R:R#G$@0I:"^) I]S#<;C#C,T*20P&&B37!PBL&T&
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M-G@Z'_[OVT>[GQ$/X)>S@_V?_A]02P,$%     @ DXN#5K!<.V\7#@  S$0
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MNUC^8"L\Q>)4GSE,"*R/H/"QB *I)R16JC"BJHZ"8$6*SF+L$K 8A^/%,U,
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MPK6+,LUDB(4G#JX>/98VDV*F+ODNDTA]W4&UOM9H?](/:(<GC3Z%J9O8X';
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M9V04RMKG*>E3$?\X.>7]"=[MWT8\QK]&(K_#*/^*R?\ 4$L! A0#%     @
MDXN#5OR EW(Z P  ^PL  !$              ( !     &%N=G,M,C R,S S
M,S$N>'-D4$L! A0#%     @ DXN#5FSRHQK_"@  ;(<  !4
M ( !:0,  &%N=G,M,C R,S S,S%?;&%B+GAM;%!+ 0(4 Q0    ( ).+@U;X
M)_2Y5 <  ,58   5              "  9L.  !A;G9S+3(P,C,P,S,Q7W!R
M92YX;6Q02P$"% ,4    " "3BX-6/9/T6[@7  # ?P  $@
M@ $B%@  =&TR,S$Q,3@P9#)?.&LN:'1M4$L! A0#%     @ DXN#5ADBA[3@
MJ0  _L8# !4              ( !"BX  '1M,C,Q,3$X,&0R7V5X,2TQ+FAT
M;5!+ 0(4 Q0    ( ).+@U:P7#MO%PX  ,Q$   5              "  1W8
M  !T;3(S,3$Q.#!D,E]E>#4M,2YH=&U02P4&      8 !@"+ 0  9^8

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
